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ABBREVIATIONS AND DEFINITIONS
ABI  Ankle-brachial index
ADP  Arteria dorsalis pedis
AFS  Amputation-free survival
APP  Assisted primary patency 
ASA  Acetosalisylic acid
ATA  Arteria tibialis anterior
ATP  Arteria tibialis posterior
AUC  Area under the (ROC) curve
CABG  Coronary artery bypass grafting
CAD  Coronary artery disease
CG  Cockcroft-Gault 
CGSV  Contralateral great saphenous vein
CKD  Chronic kidney disease
CLI  Critical limb ischaemia
COPD  Chronic obstructive pulmonary disease
CTA  Computed tomography angiography
CVD  Cerebrovascular disease
DM  Diabetes mellitus
DSA  Digital subtraction angiography
eGFR  Estimated glomerural fi ltration rate
ESRD  End-stage renal disease
GSV  Great saphenous vein
IDMS  Isotope dilution-mass spectrometry
IGSV  Ipsilateral great saphneous vein
LMWH  Low molecular weight heparin
LS  Leg salvage
LSV  Lesser saphenous vein
MDRD  Modifi cation of Diet in Renal Disease
MI  Myocardial infarction
MRA  Magnetic resonance angiography
N.A  Not assessed/not available
PTFE  Polytetrafl uoroethylene
ROC  Receiver operating characteristic
SCr  Serum creatinine
SCS  Spinal cord stimulation
SMC  Smooth muscle cell
SE  Standard error
SP  Secondary patency
TASC  Trans-Atlantic Inter-Society Consensus Document on
  Management of Peripheral Arterial Disease
Primary patency Graft patency is uninterrupted 
Assisted primary patency Graft is patent, but additional procedures have 
 been performed to maintain patency
Secondary patency Graft patency has been restored after occlusion
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8ABSTRACT
Background
Patients with critical limb ischaemia (CLI) usually have several comorbidities 
affecting the outcome. Complex and sometimes multiple infrainguinal 
bypasses are required for limb salvage. Therefore, the lack of optimal graft 
material is an increasing clinical problem. The type and quality of the vein 
graft are major determinants of bypass patency. Revascularization for CLI is 
meaningless unless both life and limb are preserved. Therefore, the knowledge 
of both patient- and bypass-related risk factors is of paramount importance in 
clinical decision-making, patient selection and resource allocation.
Aims of the study
The aim of this study was to identify patient- and graft-related predictors 
of impaired outcome after infrainguinal bypass for critical limb ischaemia. 
The purpose was to assess the outcome of high-risk patients undergoing 
infrainguinal bypass and to evaluate the usefulness of specifi c risk scoring 
methods. The results of bypasses in the absence of optimal vein graft material 
were also evaluated, and the feasibility of the new method of scaffolding 
suboptimal vein grafts was assessed.
Patients and methods
 I A retrospective study of 603 infrainguinal bypasses for critical limb 
ischaemia comparing serum creatinine (SCr) and estimated glomerular 
fi ltration rate (eGFR) as predictors of outcome.
 II A retrospective study comparing the outcome of octogenarian patients 
with CLI undergoing either infrainguinal percutaneous transluminal 
angioplasty (PTA) (n=277) or infrainguinal bypass (n=307).
 III A total of 1,425 patients undergoing infrainguinal PTA or bypass for CLI 
were analysed retrospectively and the usefulness and accuracy of two risk 
scoring methods, the Finnvasc score and modifi ed Prevent III (mPIII) 
score, as predictors of outcome were assessed. 
 IV In a retrospective analysis of 1,109 patients undergoing infrainguinal vein 
bypass for critical limb ischaemia, the patency and leg salvage rates of 
different types of autologous vein grafts were assessed. Risk factors for 
graft failure were also evaluated. 
 V A single-centre study compared the results of arm vein (n=130) and 
prosthetic (n= 160) infrainguinal bypasses for CLI.
 VI A prospective, multicentre, observational study from six centres assessed 
the feasibility of the new method of external scaffolding for suboptimal 
infrainguinal vein grafts in 50 patients.
Arvela_vk3.indd   8 14.10.2011   09:05:58
9ABSTRACT
Main results
Estimated GFR <30 ml/min/1.73 m2 and serum creatinine >200 mmol/l 
predicted mortality (the adjusted hazard ratio [HR] 4.0 [95% CI 2.22–7.39] 
and 3.5 [95% CI 1.82–6.84], respectively) and limb loss (the adjusted HR 6.5 
[95% CI 2.71–15.59] and 6.2 [95% CI 2.47–15.56], respectively) (I).
In 95 propensity-score-matched pairs, PTA achieved signifi cantly better 
leg salvage (88% vs. 75%, p = 0.010) and amputation-free survival (AFS) 
(53% vs. 45%, p = 0.033) rates than bypass in octogenarians with CLI (II).
In patients undergoing infrainguinal revascularization for CLI, the Finnvasc 
score predicted leg salvage (RR 1.431, 95% CI 1.319–1.551), survival (RR 
1.233, 95% CI 1.116–1.363) and amputation-free survival (RR 1.422, 95% 
CI 1.319–1.534). The modifi ed PIII score also predicted leg salvage (RR 
1.190, 95% CI 1.108–1.277), survival (RR 1.245, 95% CI 1.193–1.300) and 
amputation-free survival (RR 1.223, 95% CI 1.176–1.272) (III).
Primary patency, assisted primary patency, secondary patency and 
limb salvage at 1 year were signifi cantly better in the single-segment great 
saphenous vein (GSV) graft group than in the alternative autologous vein graft 
group: 74.4% vs. 53.7% (p<0.0001), 82.4% vs. 67.2% (p<0.0001), 84.8% vs. 
69.9% (p<0.0001) and 88.9% vs. 83.0% (p<0.0001), respectively. Non-single-
segment GSV graft was the only independent risk factor for graft stenosis 
development (RR 2.62, 95% CI 1.56–4.38, p<0.0001) (IV).
High-risk patients (age >80, coronary artery disease, eGFR<30) who 
underwent bypass with a risk graft (arm vein or spliced vein) had extremely 
poor one-year survival (28.6%) (IV).
In infrapopliteal revascularizations for CLI, primary patency, assisted 
primary patency and secondary patency rates at three years were signifi cantly 
better in the arm vein group than the prosthetic group: 28.3% vs. 9.6% (p=0.031), 
56.8% vs. 10.4% (p=0.000) and 57.4% vs. 11.2% (p=0.000), respectively. Leg 
salvage and survival at 3 years were 75.0% vs. 57.1% (p=0.005) and 58.8% 
vs. 39.5% (p=0.007), respectively (V).
The six-month primary, assisted primary and secondary patency rates of 
bypasses using external mesh support due to a suboptimal quality of vein 
grafts were acceptable: 82.3%, 88.6% and 92.1%, respectively. No adverse 
effects related to polyester mesh were detected (VI).
Conclusions
Low estimated GFR is an independent marker of poor prognosis after 
infrainguinal bypass in patients with critical limb ischaemia. Estimated GFR 
is a more accurate predictor of survival and leg salvage than serum creatinine 
alone (I).
The overall outcome of octogenarians with critical limb ischaemia 
undergoing infrainguinal revascularization is poor. Endovascular treatment 
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seems to be associated with better survival, leg salvage and amputation-
free survival than bypass. If feasible, an endovascular fi rst option should be 
considered in patients ≥ 80 years of age, especially in the presence of coronary 
artery disease (II).
The Finnvasc and modifi ed Prevent III risk scoring methods predict the 
long-term outcome of patients undergoing both surgical and endovascular 
infrainguinal revascularization for CLI. The Finnvasc score also seems to 
perform well in predicting immediate postoperative outcome. Both risk scores 
may be useful as additional information in decision-making (III).
A single-segment great saphenous vein graft is superior to any other 
autologous vein graft in terms of mid-term patency and leg salvage. A single-
segment GSV graft requires fewer maintenance procedures than alternative 
autologous vein grafts. Acceptable patency and leg salvage rates can be 
achieved with alternative autologous vein grafts (IV).
The outcome of patients with both a high operative risk and a risk graft 
bypass is very poor (IV).
Arm vein conduits are superior to prosthetic grafts for infrapopliteal bypasses 
in patients with CLI. Despite only moderate patency rates, a prosthetic bypass 
on infrapopliteal arteries may be worthwhile as a last resort option for limb 
salvage (V).
In a prospective, multicenter study of 50 patients, polyester mesh seems 
to be a safe and feasible adjunct to infrainguinal bypass using suboptimal 
autologous vein grafts, and it may enable the use of vein grafts of compromised 
quality (VI).
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INTRODUCTION
Peripheral arterial disease (PAD) can be defi ned as a disparity between tissue 
oxygen demand and supply. Critical limb ischaemia (CLI) is an end-stage PAD 
where chronic lack of suffi cient blood supply eventually leads to ischaemic rest 
pain and/or a tissue lesion. According to Norgren et al. (2007), the estimated 
incidence of CLI varies between 500 and 1,000/million annually.
Asymptomatic PAD and claudication are markers of increased cardiovascular 
risk (Shammas 2007) but infrequently lead to limb loss (Dormandy and Murray 
1991). Critical limb ischaemia (ischaemic rest pain or ischaemic tissue lesion) 
often leads to limb loss without revascularization (Wolfe and Wyatt 1997).
The main purpose of revascularization procedures for CLI is to preserve the 
leg and sustain the patient’s ambulatory status. Other goals are ischaemic pain 
relief and healing of ischaemic ulcers. CLI patients who undergo successful 
revascularization sustain their mobility and independent status longer (Luther 
1998) and have better survival and quality of life (Klevsgård et al. 2001, Brosi 
et al. 2007) than those treated conservatively or with primary amputation. An 
active revascularization policy for CLI reduces amputation rates (Eskelinen et 
al. 2004) and has proven cost-effective in ambulatory patients (Luther 1997). 
Therefore, revascularization should be offered to all CLI patients if the procedure 
can be tolerated and the patient is ambulatory and living independently 
preoperatively (Varu et al. 2010). According to the fi rst TransAtlantic Inter-
Society Consensus (TASC) document (2000), primary amputation should be 
considered in the presence of an unreconstructable disease, extensive necrosis 
involving weight-bearing areas, a fi xed and irremediable fl exion contracture 
of the leg, a terminal illness, or a very limited life expectancy because of co-
morbid conditions.
Endovascular revascularization procedures have challenged bypass surgery 
as the fi rst-line treatment for CLI (Nasr et al. 2002, Kudo et al. 2004). This 
is mainly due to their less invasive nature and subsequent better short-term 
survival especially in elderly patients (Doslouglu et al. 2009). Despite rapidly 
evolving endovascular techniques, there are still patients with multilevel 
infrainguinal disease not amenable to endovascular procedures. The latest 
TASC II Document still recommends bypass surgery as the treatment of choice 
for long multisegmental lesions (Norgren et al. 2007). The BASIL Trial—a 
large randomised trial comparing bypass and endovascular revascularization—
suggests that bypass provides more durable results than the endovascular 
approach and, therefore, a bypass-fi rst strategy should be considered if there 
is a good vein and the patient is relatively fi t with a life expectancy more than 
two years (Adam et al. 2005, Bradbury et al. 2010).
Despite the technical success and acceptable patency rates of bypass 
procedures, advanced age and co-morbid conditions may limit the benefi t 
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from bypass procedures. Advanced age is associated with decreased peri- 
and postoperative survival after vascular surgery procedures (Plecha et al. 
1985). Renal insuffi ciency is an independent predictor of impaired outcome. 
Especially patients with end-stage renal disease (ESRD) and critical limb 
ischaemia undergoing infrainguinal bypass have poorer post-operative survival 
and higher amputation rates (Sanchez et al. 1992, Johnson et al. 1995). The 
combination of ESRD, coronary artery disease, hypoalbuminaemia and critical 
limb ischaemia seems to be a marker of extremely poor outcome (Biancari et 
al. 2002). 
In addition to patient characteristics, several graft-related factors affect 
the outcome. Outfl ow is one of the most important determinants of bypass 
outcome (Albäck et al. 1998). Graft type, size and quality are also major 
contributors to bypass patency. The great saphenous vein (GSV) is the conduit 
of choice for infrainguinal bypass due to its superior long-term patency and 
limb salvage rates (Klinkert et al. 2004, Perreira et al. 2006). As a result of 
a previous infrainguinal bypass, coronary artery bypass grafting, or varicose 
vein surgery or ablation, however, the GSV may be lacking or can be of poor 
quality due to varicosities or small calibre. In these cases, either alternative 
autologous veins or prosthetic material can be used as conduits. Acceptable 
patency and leg salvage rates can be achieved with alternative autologous 
veins (Gentile et al. 1996, Faries et al. 2000a-c). The patency and leg salvage 
of prosthetic bypasses are promising in the femoro-popliteal level and in the 
short term (Veith et al. 1986, Bosiers et al. 2006, Peeters et al. 2006), but the 
long-term outcome of infrapopliteal prosthetic bypasses is still poor (Kashyap 
et al. 2002). Adjunctive methods such as heparin-bonding (Peeters et al. 2006) 
and anastomotic modifi cations (Gulkarov et al. 2008) have been introduced to 
improve the results of prosthetic bypasses. 
As the population is aging and the incidence of diabetes increasing, even 
more elderly patients with CLI and numerous co-morbidities will be referred to 
vascular surgery units (Conte et al. 2001, Diehm et al. 2004). This emphasizes 
the role of patient selection and preoperative risk assessment in the future. The 
estimation of the risk of adverse postoperative outcome is important as it helps 
decision-making between different treatment modalities, allows appropriate 
resource allocation and provides patients with information of their individual 
operative risk. 
This study evaluates patients undergoing infrainguinal bypass for CLI. 
The aim was to uncover patient- and graft-related predictors of poor outcome 
and to assess whether the results of infrainguinal bypasses in suboptimal 
circumstances are good enough to justify these high-risk procedures. The 
results of this study might be helpful in every-day clinical practise, guiding 
vascular surgeons in patient selection and clinical decision-making in regard 
to which treatment modality should be chosen and when to refrain from any 
type of reconstruction.
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REVIEW OF THE LITERATURE
1 OUTCOME OF PATIENTS WITH CRITICAL LIMB 
ISCHAEMIA
1.1 Natural outcome
Manifestations of PAD can be classifi ed according to the severity of ischaemia 
by using the Fontaine classifi cation (Fontaine et al. 1955; Table I) or the 
Rutherford classifi cation (Rutherford et al. 1986; Table II). Asymptomatic 
PAD (Fontaine I, Rutherford 0) or claudication (Fontaine II a-b, Rutherford 
1-3) are markers of increased cardiovascular risk (Shammas et al. 2007) but 
only seldom lead to limb loss (Dormandy and Murray 1991). In contrast, 
ischaemic rest pain (Fontaine III, Rutherford 4) or an ischaemic tissue lesion 
(Fontaine IV, Rutherford 5–6) often leads to limb loss without revascularization 
procedures (Wolfe and Wyatt 1997).
Table I. Fontaine classifi cation Table II. Rutherford classifi cation
The international consensus on the defi nition of CLI is as follows: any patient 
with chronic ischaemic pain, an ulcer or gangrene attributable to objectively 
proved arterial occlusive disease (Norgren et al. 2007). Patients with CLI are 
estimated to represent approximately 1% of the total number of PAD patients 
(Hirsch et al. 2006). Patients with CLI are not only at a high risk of losing 
their limb, but also at risk for other cardiovascular events, such as myocardial 
infarction and stroke (Howell et al. 1989, McKenna et al. 1991, Criqui et al. 
1992, Murabito et al. 2002). Up to 80% of CLI patients die from a vascular 
event; over 60% from coronary artery disease (CAD) and approximately 10% 
from stroke (Regensteiner and Hiatt 2002). High mortality rates associated 
with diagnosed CLI even exceed those seen in patients with symptomatic 
coronary artery disease (Caro et al. 2005, Steg et al. 2007), which emphasizes 
Stage Clinical description
I Asymptomatic
IIa Mild claudication
IIb Moderate-severe claudication
III Rest pain
IV Ulcer or gangrene
Stage Clinical description
0 Asymptomatic
1 Mild claudication
2 Moderate claudication
3 Severe claudication
4 Rest pain
5 Minor tissue loss
6 Severe tissue loss
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the role of the severe diffuse atherosclerotic burden of CLI. CLI is therefore 
a predictor of poor prognosis for both life and limb. The prognosis of CLI is 
even compared to that of some malignant diseases as the mortality is 20% 
in the fi rst year after presentation and seems to continue at the same rate, 
reaching 50% at 5 years and 90% at 10 years (Norgren et al. 2007). Moreover, 
studies on patients diagnosed with CLI reveal that at 1 year, only 50% patients 
will remain amputation-free, some of them still symptomatic, whereas 25% 
will require a major amputation and the remaining 25% will die (Norgren 
et al. 2007). An observational study of 105 patients with unreconstructed 
CLI published by Lepäntalo and Mätzke (1996) demonstrates an even 
worse outcome, as the 1-year survival and leg salvage rates were 46% and 
54%, respectively. The one-year amputation-free survival was only 28%. 
Seventy-two percent of patients died due to cardiovascular events. Similarly, 
data from multicentre pharmacotherapy trials on patients with CLI who are 
unreconstructable or in whom reconstruction attempts have failed show that 
within 6 months approximately 40% lose their limb and 20% die (Norgren et 
al. 2007). The fate of the unreconstructed CLI patient is reported to be dismal 
in other series as well (Table III). 
The degree of ischaemia is a major contributor to the fate of the leg. 
According to Wolfe and Wyatt (1997), the amputation rate in the presence 
of subcritical (rest pain and/or ankle pressure > 40 mmHg) versus critical 
limb ischaemia (tissue loss and/or ankle pressure < 40 mmHg) without 
reconstruction at one year was 70% versus 95%, respectively.
Table III. Fate of unreconstructed CLI
Author (year) n FU (months) amputation (%) mortality (%)
Norgren et al. (1990) 103a 6 39 13
Jivegård et al. (1995) 51b 18 45 31
Lepäntalo & Mätzke (1996) 105 12 46 54
Klomp et al. (1999) 120c 24 45 33
Amann et al. (2003) 112d 12 35 -
FU=follow-up
aprostanoid treatment n=50, placebo n=53
bspinal cord stimulation (SCS) n=25, control n=26 
cSCS n=60, control n=60
dSCS n=73, control n=39
The effect of alternative treatment modalities has also been studied in patients 
with CLI not eligible for revascularization. Placebo-controlled studies have 
evaluated the use of prostacyclin analogues in the treatment of CLI. Neither 
Norgren et al. (1990) nor Brass et al. (2006) found any difference in amputation 
rates between the prostacyclin analogues and the placebo group. Therefore, 
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these pharmacologic agents seem to have no role in the management of 
CLI. Spinal cord stimulation (SCS) has been introduced as an alternative to 
amputation in CLI patients with severe ischaemic pain. Ubbink et al. (2006) 
reported positive effects of SCS on pain relief, but concluded that the risks 
and high cost must be weighed against the marginal benefi ts. Klomp et al. 
(1999) concluded that spinal cord stimulation in addition to the best medical 
care does not prevent amputation in patients with critical limb ischaemia. 
Dedicated wound care may increase limb salvage in some patients who are 
unfi t for surgery (Marston et al. 2006).
1.2 Outcome of infrainguinal bypass
The outcome of infrainguinal bypass can be defi ned in many ways. The 
purpose of revascularization is to relieve ischaemic pain, heal ischaemic 
tissue lesions, prevent amputation and therefore sustain ambulatory status, 
as well as to improve the quality of life and prolong survival. According to 
Nicoloff and co-workers (1998), an ideal endpoint—i.e., a patent graft, healed 
wound, freedom from reoperations, independent living status and continued 
ambulation—was rarely achieved in patients with CLI, as only 14% of the 
patients met all these criteria for success. Similarly, Colledge and colleagues 
(2001) used the same criteria for successful revascularization and reported 
that only 22% of CLI patients achieved the ideal outcome.
Both patient- and bypass-related factors affect the overall outcome. Bypass 
patency and leg salvage are largely dependent on arterial anatomy and bypass 
graft- related factors, such as graft type and quality. Table IV summarizes 
the patency and leg salvage expectations for different types of infrainguinal 
bypasses as reported in a review by Dahlman (2000). Patient survival and 
functional outcome, on the other hand, are affected mostly by co-morbidities 
and medication. Death usually predominates in patients with CLI and, 
therefore, other endpoints, such as wound healing, are not easily assessed. 
There is controversy regarding the most appropriate endpoint in the 
evaluation of patients with CLI. The preservation of both life and limb is 
of paramount importance, and therefore amputation-free survival (AFS) is 
a justifi able endpoint. Furthermore, the TASC II Document (Norgren et al. 
2007) suggests AFS as a primary outcome endpoint. In a large randomised, 
multicentre trial including 1,166 patients undergoing infrainguinal bypass 
for CLI, Schanzer et al. (2009) reported a 79% AFS at 1 year. In the largest 
randomised trial comparing bypass versus angioplasty in the treatment of 
severely ischaemic leg (the BASIL Trial), one-year amputation-free survival 
after bypass was reported to be 68% (Adam et al. 2005). Similarly, Feinglass 
and co-workers (2001) reported 1-year and 3-year amputation-free survival 
rates of 74% and 56%, respectively, in their series from Veterans Affairs 
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hospitals including 4,288 male veterans undergoing femorodistal bypass 
(63% of study population had CLI). Due to the high incidence of severe 
comorbidities, perioperative (<30-day) mortality is relatively high in CLI 
patients undergoing infrainguinal bypass. A meta-analysis reviewing 31 
studies involving bypass for CLI (Albers et al. 2006) revealed considerably 
high immediate postoperative mortality up to 11.6% (weighted average 2.3%). 
In a review of 10 studies reporting the outcomes of femoropopliteal bypass 
grafting, Hunink et al. (1994) published a 3.6% overall perioperative mortality 
rate. In the large Prevent III study, the overall perioperative mortality rate was 
2.7% (Conte et al. 2005). 
Table IV. Patency and leg salvage expectations for diff erent types of infrainguinal 
bypasses (Dahlman 2000).
PP SP LS
1Y 3Y 1Y 3Y 1Y 3Y
A-K FEMOROPOPLITEAL
GSV* 84% 73% - - - -
arm vein 82% 60% - - - -
PTFE 75% 66% - - - -
B-K FEMOROPOPLITEAL 
GSV** 80% 73% 96% 86% 99% 83%
arm vein - - 83% 73% - -
PTFE - - 68% 44% - -
INFRAPOPLITEAL
GSV
reversed 77% 66% 84% 78% 85% 82%
in-situ 82% 74% 89% 84% 91% 83%
arm vein - - 73% 58% -
PTFE - - 46% - 68% 56%
PEDAL/PLANTAR
GSV* 81% - 85% 76% 83% 84%
A-K= above-knee, B-K= below-knee
GSV=great saphenous vein, PTFE= polytetrafl uoroethylene
PP= Primary patency, SP= Secondary patency, LS= Leg salvage
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2 FACTORS AFFECTING THE OUTCOME OF 
INFRAINGUINAL BYPASS
2.1 Patient-related risk factors
Patients with CLI often also have other manifestations of cardiovascular 
disease (CAD, cerebrovascular disease [CVD]) as well as other comorbidities 
such as diabetes, chronic obstructive pulmonary disease (COPD) and renal 
insuffi ciency, which affect the outcome negatively and largely determine the 
fate of the patient regardless of the success of the bypass procedure alone. 
2.1.1 Coronary artery disease
Coronary artery disease has been estimated to be present in over 50% of 
patients with CLI (Feringa et al. 2007, Norgren et al. 2007). The risk of 
cardiac events in patients with CLI seems to be at least equal that of patients 
with symptomatic CAD (Criqui et al. 1992, Newman et al. 1999). High 
cardiac event and mortality rates with a 5-year survival of 60%–70% in CLI 
patients undergoing revascularization are reported in several series (Dawson 
et al. 1993, Farkouh et al. 1994). Myocardial infarction (MI) is the most 
common life-threatening complication of vascular surgery, with a reported 
perioperative incidence ranging from 8% to up to 40%, depending on the 
diagnostic criteria (Kim et al. 2002, Landensburg et al. 2003, Hobbs et al. 
2005). The severity of PAD is clearly connected to the risk of coronary events 
(Criqui et al. 1992, Newman et al. 1999), and CLI defi nitely represents the 
worst phase of the condition. One explanation for the high perioperative 
MI rate in CLI might be that patients undergoing surgery for CLI have even 
greater levels of platelet and monocyte activation than those being treated for 
acute MI (Burdess et al. 2010). Conte and co-workers (2005) reported a 4.7% 
perioperative myocardial infarction rate after infrainguinal bypass for CLI, and 
the notable fi nding was that 24% of the patients had no kind of antithrombotic 
medication. The best medical treatment is of paramount importance in order 
to reduce perioperative adverse cardiac events. Pharmacological treatment 
with β-blockers, statins and aspirin are demonstrated to have benefi cial effects 
(Poldermans et al. 2009). However, according to two randomised controlled 
trials, CARP (Coronary Artery Revascularization Prophylaxis; McFalls et al. 
2004) and the DECREASE-V Trial (Poldermans et al. 2007), prophylactic 
coronary artery revascularization in cardiac stable patients does not seem to 
provide any signifi cant extra benefi t in terms of postoperative outcome, with 
an exception for patients with left main coronary artery stenosis. Therefore, 
in the most recent European Society for Cardiology (ESC) guidelines, it is 
only recommended to consider prophylactic coronary artery revascularization 
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in patients undergoing high-risk surgery, such as lower extremity open 
revascularization (Poldermans et al. 2009).
2.1.2 Diabetes
Diabetes increases the prevalence of symptomatic peripheral arterial disease 
3.5-fold in men and 8.6-fold in women (Kannel and McGee 1985). Poor 
glucose control accelerates the manifestation of peripheral arterial disease. 
For every 1% increase in haemoglobin A1c, there is a corresponding increase 
of 25%–28% in the relative risk of peripheral arterial disease (Selvin et al. 
2004). Among patients with PAD, diabetes is associated with an approximately 
fourfold increase in the risk of developing CLI (Norgren et al. 2007). Ten 
to twenty years ago, roughly one third of patients undergoing infrainguinal 
bypass for CLI had diabetes (Da Silva et al. 1996), but currently there are as 
many diabetics as non-diabetics among patients with CLI (Conte et al. 2001, 
Eskelinen et al. 2004), and in the future diabetics will overtake non-diabetics, 
especially if the more liberal defi nition of CLI is used (Apelqvist et al. 2008). 
Diabetes does not seem to have an effect on graft patency (Biancari 2000a, 
Wölfl e et al. 2003, Monahan and Owens 2009). The effect of diabetes on leg 
salvage and survival is, however, controversial. According to previous studies, 
the clinical results of lower extremity bypass surgery seem to be worse in 
diabetics in terms of increased mortality (Stirnemann et al. 1991, Karacagil et 
al. 1995, Luther and Lepäntalo 1997a, Biancari et al. 2000a, Wölfe et al. 2003) 
and inferior limb salvage rates (Taylor et al. 1990, Da Silva 1996, Luther 
and Lepäntalo 1997a). The manifestation of peripheral arterial disease is 
often different in diabetics and nondiabetics. The combined effect of diabetic 
neuropathy and ischaemia, so-called neuroischaemia, affects the foot perfusion 
in a variety of ways (Schaper et al. 2000). Infection and impaired wound 
healing are evidently major determinants of leg salvage in diabetic patients. 
Unfortunately, up to 30% of diabetics have gangrene at admission to a vascular 
surgery unit due to a lack of recognition of ischaemia, an underestimation of 
the severity of the lesion and a subsequent delay in referral (Mills et al. 1991). 
The prevalence of diabetic foot ulcers has been estimated to be 3%–8% (Abbot 
et al. 1998, Reiber et al. 1998). Approximately 40%–60% of all amputations 
of the lower extremity are performed on patients with diabetes (Larsson 
and Apelqvist 1995, Adler et al. 1999) Up to 85% of these amputations are 
precipitated by a foot ulcer which deteriorates to deep infection or gangrene 
(Larsson et al. 1995, Reiber et al. 1998). In the series of Carsten et al. (1998), 
persistent overwhelming soft tissue infection despite a patent bypass was the 
reason for early amputations in 4.4% of patients. Similarly, Virkkunen and co-
workers (2004) reported that after bypass for CLI, signifi cantly more diabetics 
than non-diabetics underwent amputation despite successful revascularization. 
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There are, however, recent studies suggesting that diabetic patients with CLI 
could achieve an equal outcome after infrainguinal bypass as non-diabetic 
patients with an aggressive, multidisciplinary approach, including experience 
in extremely distal revascularizations as well as aggressive treatment of 
infection, frequent debridement, biomechanical off-loading, blood glucose 
control and treatment of co-morbidities (Akbari et al. 2000, Dorweiler et al. 
2002, Awad et al. 2006).
2.1.3 Renal insuffi  ciency
Approximately 5% of patients with end-stage renal disease (ESRD) develop 
critical limb ischaemia (Albers et al. 2001), and bypass surgery for CLI 
on patients with renal insuffi ciency, especially ESRD, is challenging. 
Cardiovascular mortality is higher among patients with end-stage renal 
disease in comparison to the normal population (Sarnak and Levey 2000). 
Diabetes and hypertension are not only risk factors for both ESRD and CLI, 
but may further worsen the prognosis (Longenecker et al. 2002, Kronenberg et 
al. 2003). However, renal insuffi ciency per se seems to be an independent risk 
factor for poor outcome (Naidu et al. 2003, Go et al. 2004).
Dialysis-dependent patients usually have extremely calcifi ed arteries, 
and their wound healing is impaired due to several factors, such as anaemia, 
malnutrition, impaired immunity and a susceptibility to infection (Sanchez et 
al. 1992, Whittemore et al. 1993, Peltonen et al. 1998). Therefore, patients with 
critical limb ischaemia and ESRD undergoing infrainguinal bypass have poorer 
post-operative survival and higher amputation rates. The patency rates of ESRD 
patients are comparable to patients with normal kidney function (Hakaim et al. 
1998), but a 10%–37% amputation rate due to persistent gangrene despite a 
patent bypass has been reported in ESRD patients (Edwards et al. 1988, Taylor 
et al. 1991, Johnson et al. 1995, Simsir et al. 1995, Albers et al. 2007). A meta-
analysis by Albers et al. (2007) yielded a 5-year pooled estimate of 50.4% 
for primary patency, 50.8% for secondary patency and 66.6% for leg salvage. 
Five-year survival was only 23%. Especially in diabetic patients with ESRD, 
the outcome has been discouraging because of high perioperative mortality 
rates (3%–17%) and low 3-year leg salvage rates (40%–76%) (Edwards et 
al. 1988, Harrington et al. 1990, Whittemore et al. 1993, Johnson et al. 1995, 
Harpavat et al. 1998). Furthermore, the life expectancy after bypass in this 
patient group has been reported to be dismal, with an average of 60% survival 
at 1 year, 50% survival at 2 years, and 0%–40 % survival at 3 years (Harpavat 
et al. 1998, Edwards et al. 1988, Chang et al. 1990, Harrington et al. 1990, 
Whittemore et al. 1993, Johnson et al. 1995, Simsir et al. 1995, Hakaim et al. 
1998). End-stage renal disease is evidently a marker of poor prognosis, but the 
impact of mild to moderate renal insuffi ciency on outcome after infrainguinal 
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bypass for CLI is less well known. O’Hare et al. (2004) reported that PAD 
patients on dialysis, but not patients with milder degrees of renal insuffi ciency, 
are at higher risk of limb loss after revascularization when compared to patients 
with normal renal function. 
The measurement of serum creatinine is the most commonly used method 
to assess renal function, but it is an inaccurate estimate of actual renal function, 
especially in early renal insuffi ciency (Diskin 2007). Direct measurement of 
glomerular fi ltration rate is the gold standard, but it is not practical in clinical 
use. The glomerular fi ltration rate can be estimated with serum-creatinine-
based equations; either the Modifi cation of Diet in renal Disease (MDRD; 
Levey et al. 1999) or the Cockcroft-Gault (Cockcroft and Gault 1976) 
formula. These formulas take age, sex and body size into consideration and 
are therefore more accurate in estimating renal function than serum creatinine 
alone. Maithel et al. (2006) showed that, independently of dialysis status, 
estimated GFR, but not serum creatinine, also predicted long-term survival 
after lower limb revascularization
2.1.4 Age
As a result of the increasing life expectancy of the population, more 
octogenarians and even older patients with critical limb ischaemia are being 
referred to vascular surgery units (Pomposelli et al. 1998, Diehm et al. 2004). 
Several studies have demonstrated that equal patency and limb salvage rates 
after infrainguinal bypass can be achieved in octogenarians as in younger 
patients (Luther and Lepäntalo 1997a and 1997b, Pomposelli et al. 1998, 
Chang and Stein 2001, Brosi et al. 2007). Doslougly and co-workers (2009) 
even reported superior limb salvage rates in octogenarians compared to those 
of younger patients undergoing infrainguinal bypass. The explanation for this 
is probably the patient selection, with a smaller proportion of diabetics, active 
smokers and patients with ESRD in octogenarians. Furthermore, infrainguinal 
bypass for CLI in patients aged 80 years and older is justifi ed because limb 
preservation is likely to sustain ambulatory status and independent living 
(Luther and Lepäntalo 1997b, Pomposelli et al. 1998, Zdanowski et al. 
1998). Despite its proven effectiveness, the overall benefi t from infrainguinal 
bypass may, however, be limited in the very elderly because advanced age 
is associated with increased perioperative and postoperative mortality after 
vascular operations (Plecha et al. 1985). Perioperative mortality rates in series 
of octogenarians undergoing infrainguinal bypass is reported to be relatively 
high, 2%–16% (Scher et al. 1986, O’Mara et al. 1997, Pomposelli et al. 1998, 
Chang and Stein 2001, Doslouglu et al. 2009). Five-year survival rates for 
octogenarians with CLI are reported in the literature to range from 25 to 54 
percent (Pomposelli et al. 1998, Chang and Stein 2001, Doslouglu et al. 2009), 
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which is considerably worse than the 77% 5-year survival rate reported in a 
series of patients of the same age undergoing coronary artery bypass grafting 
(Nissinen et al. 2010). This again underlines the negative effect of not just 
age but also the presence of CLI on outcome. Advanced age in combination 
with advanced CLI seems to predict cardiovascular complications. Conte et al. 
(2005) presented pooled data from prospective multicentre trials of bypass for 
CLI (Prevent III, Circulase II and BASIL) and concluded that age>80 years 
in combination with tissue loss was associated with a 3.1-fold risk of major 
adverse cardiac events.
2.1.5 Smoking
Smoking is one of the major risk factors for CLI (Dormandy et al. 1999). It is 
associated with an approximately threefold increase in the risk of developing 
CLI in patients with PAD (Norgren et al. 2007). Tobacco smoking accelerates 
atherosclerosis in both the peripheral and the coronary arteries (Doll and 
Peto 1976, Kannel 1981). The mechanism is speculated to be vasospasm, 
hypoxia or endothelial cell loss (Davies et al. 1985, Cough 1986) and platelet 
activation (Hawkins 1972). In vitro and animal studies of intimal hyperplasia 
have demonstrated the potential of tobacco derivatives to stimulate the 
proliferation of smooth muscle cells (Davies 1985, Higman et al. 1993) and to 
inhibit the activity of endothelial nitric oxide synthase (Higman et al. 1996), 
thereby causing focal vein graft stenosis. Furthermore, several clinical series 
have demonstrated that smoking is associated with vein bypass graft stenosis 
(Wiseman et al. 1989, Powel et al. 1993, Cooke and Ma 1995, Cheshire et 
al. 1996). Smoking has been associated with an increased risk of occlusion 
of femoropopliteal saphenous vein grafts. Wiseman et al. (1989) reported 
a 1-year patency of 63% for smokers as opposed to the 84% rate for non-
smokers. Gentile et al. (1997) reported that of the traditional cardiovascular 
risk factors, only smoking was associated with early graft fl ow disturbances. 
Willigendael et al. (2005) published a meta-analysis including 29 studies (4 
randomized clinical trials, 12 prospective studies and 13 retrospective studies) 
assessing the effect of smoking on vein graft failure. Based on the results 
of randomized clinical trials and other prospective studies, they concluded 
that continued smoking after lower limb bypass surgery results in a threefold 
increased risk of graft failure. According to Bluman and co-workers (1989), 
current smoking increases the risk of postoperative pulmonary complications 
nearly sixfold. This risk seems to exist even with no diagnosed chronic 
pulmonary disease.
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2.1.6 Chronic obstructive pulmonary disease
Data concerning the impact of chronic obstructive pulmonary disease (COPD) 
on the outcome of patients undergoing infrainguinal bypass for CLI is sparse in 
the literature. Diagnosed chronic lung disease is, however, the most signifi cant 
patient-related risk factor for postoperative pulmonary complications. The 
relative risk is reported to range from 3% to 6% (Smetana 1999). McAllister 
and co-workers (2003) reported that patients with COPD had an up to 
300%–700% higher risk of postoperative pulmonary complications than 
those without COPD. Despite the increased risk of postoperative respiratory 
complications, there seems to be no prohibitive level of lung function below 
which surgery would be absolutely contraindicated (Stein 1970, Smetana 
1999). Bronchodilators, smoking cessation, antibiotics and/or corticosteroids 
along with chest physical therapy reduce the risk of pulmonary complications 
in COPD patients undergoing surgical procedures (Stein 1970, Tarhan 
1973). Furthermore, epidural anaesthesia is associated with a reduced risk of 
pulmonary complications when compared to general anaesthesia in COPD 
patients (van Lier et al. 2011).
2.1.7 Hypercoaguable states 
Hypercoaguable states can be the underlying cause of accelerated peripheral 
arterial disease (Donaldson 1993) and should be suspected in cases of arterial 
thrombosis in unexpectedly young patients or without traditional risk factors 
for PAD. Resistance to activated protein C (factor V Leiden mutation), 
antithrombin defi ciency, protein C and protein S defi ciency as well as 
antiphospholipid antibody syndrome are the most common hypercoaguable 
states associated with an increased risk of arterial and venous thrombosis 
(Girolami et al. 1997). Hyperhomocysteinaemia can also be considered a 
hypercoaguable state. High serum homocysteine levels have been correlated 
with increased incidence of peripheral vascular disease, coronary artery 
disease and cerebrovascular disease (Clarke et al. 1991). The prevalence of 
hypercoaguable states is higher in patients undergoing peripheral vascular 
procedures. According to Donaldson and colleagues (1990), up to 10% of 
patients screened at their centre were found to have a serologically proven 
hypercoaguable state, whereas Ray et al. (1997) reported that as many as 35% 
of patients undergoing elective bypass surgery for leg ischaemia (CLI 77%) 
were found to have coaguability abnormalities preoperatively. Coagulation 
disorders are a risk factor not only for early (Ray et al. 1997) but also late vein 
graft failure (Curi et al. 2003). Curi et al. (2003) reported in their series of 456 
patients undergoing infrainguinal bypass that patients with hypercoaguability 
were signifi cantly younger and more likely to have undergone prior 
revascularization attempts. Patients with hypercoacuable states had poorer 
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primary patency (28% vs. 35%; p=0 .004), assisted primary patency (37% vs. 
45%; p =0.0001), secondary patency (41% vs. 53%; p=0.0001), limb salvage 
(55% vs. 67%; p= 0.009) and survival (61% vs. 74%; p =0.02) rates at 5 years. 
In addition to screened coaculopaties, neoplasia, stress and infl ammation can 
also induce a hypercoaguable state (Monahan and Owens 2009). Another 
clinically relevant phenomenon is resistance to antiplatelet therapy. Some 
patients have adverse cardiovascular events despite having dual antiplatelet 
therapy. Lepäntalo et al. (2009) concluded that concomitant aspirin and 
clopidogrel treatment failed to suppress platelet activity in 20% of patients.
2.1.8 Degree of ischaemia
There is evidence that not all cases of critical limb ischaemia are similar 
from the point of view of outcome. The status of the foot in addition to 
comorbidities is a major determinant of outcome, especially in terms of leg 
salvage. Sometimes major amputation is required despite a patent bypass graft 
because of irreversible ischaemic tissue changes and infection (Biancari et al. 
2000b, Mätzke et al. 2001). Gangrene seems to be a stronger predictor of not 
only amputation but also inferior patency than rest pain or ulcer. Nasr et al. 
(2003) reported different outcomes for different manifestations of CLI in their 
series of 128 patients with CLI undergoing 152 infrainguinal bypasses. The 
5-year primary patency, assisted primary patency and secondary patency rates 
were 33%, 52% and 51% (p = 0.04); 46%, 70% and 72% (p = 0.01) and 48%, 
76% and 75% (p = 0.003) for gangrene, ulceration and rest pain, respectively. 
The limb salvage rates also differed signifi cantly: the respective 5-year limb 
salvage rates were 59% for gangrene, 87% for ulceration and 83% for rest 
pain (p = 0.01). Therefore, the authors concluded that gangrene is a distinct 
subcategory of critical limb ischaemia with a clearly worse prognosis than 
ulceration and rest pain. 
2.2 Risk assessment
Estimation of the risk of impaired postoperative outcome is of paramount 
importance in bypass surgery for CLI, as it may guide the clinician in the 
decision-making process, provide the patients with information on their 
individual operative risk, allow the planning of resource utilization and enable 
comparison between different institutions or surgeons. Two specifi c risk 
scoring methods have been introduced and validated in literature; the Finnvasc 
(Biancari et al. 2007) and the Prevent III score (Schantzer at al 2008).
The Finnvasc score was derived from a large national series of 3,925 
patients who underwent infrainguinal bypass for CLI and whose data were 
included in the nationwide Finnvasc registry (Biancari et al. 2007). Diabetes, 
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coronary artery disease, foot gangrene and urgent operation were independent 
predictors of 30-day postoperative mortality and/or major lower-limb 
amputation, and the Finnvasc risk scoring method was therefore developed by 
assigning 1 point each to these four risk factors (Figure 1).
RISK FACTOR POINTS
Diabetes 1
Coronary artery disease 1
Foot gangrene 1
Urgent operation 1
Figure 1. Finnvasc score calculation and thirty-day combined mortality or limb loss 
rates according to diff erent risk scores in the derivation and validation datasets (Biancari 
et al 2007).
The Prevent III (PIII) risk scoring method was originally derived from a 
prospective, randomized study on the effi cacy of edifoligide in preventing 
autologous vein graft failure in 1,404 patients who underwent infrainguinal 
vein bypass surgery for CLI (Schantzer at al 2008). This risk score was 
validated both internally and externally with three independent cohorts in a 
total of 3,286 patients with CLI (Shanzer et al. 2009) to predict AFS in CLI 
patients undergoing infrainguinal bypass. Points for the calculation of original 
PIII score were assigned to each patient for the presence of dialysis (4 points), 
tissue loss (3 points), age >75 years (2 points), hematocrit <30% (2 points) 
and coronary artery disease (1 point). A score was calculated as the total sum 
of points. According to this score, patients were categorized in the low- (score 
< 3), medium- (score 4–7), or high-risk (score> 8) category (Figure 2a). A 
modifi ed version of the PIII score was published a year later by the same authors 
(Schantzer et al. 2009). In this modifi ed version, baseline hematocrit was not 
included due to a large proportion of missing values. Points for the calculation 
of the modifi ed PIII were assigned to each patient for the presence of dialysis 
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(4 points), tissue loss (3 points), age >75 years (2 points) and coronary artery 
disease (1 point). A score was calculated from the total sum of points similarly 
to the original version, and patients were categorized in the low- (score < 3), 
medium- (score 4–7), or high-risk (score> 8) category (Figure 2b).
RISK FACTOR POINTS
Dialysis
Tissue loss
Age >75 years
Hematocrit <30%
CAD
4
3
2
2
1
Figure 2a. The original Prevent III score calculation and one- year amputation-free 
survival rates according to diff erent risk score categories (Schanzer et al. 2008).
RISK FACTOR POINTS
Dialysis
Tissue loss
Age >75 years
CAD
4
3
2
1
Figure 2b. A modifi ed Prevent III score  calculation and one-year amputation-free 
survival rates according to diff erent risk score categories (Schanzer et al. 2009).
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2.3 Bypass-related factors
Patient-related factors are major contributors to overall postoperative 
survival, whereas bypass-related factors mostly determine graft patency and 
subsequently infl uence the leg salvage, although graft occlusion does not 
always lead to limb loss.
2.3.1 Run-off 
Run-off status is evidently an important determinant of bypass outcome. A lack 
of a suitable outfl ow vessel makes the revascularization impossible. Inadequate 
outfl ow is a well-reported predictor of bypass failure (Donaldson et al. 1990, 
Varty et al. 1993). There are several ways of describing run-off. The run-of 
score is a scoring method that has been developed to grade outfl ow according to 
angiographic fi ndings. This scoring method published by the Ad Hoc Committee 
in 1986 and revised in 1997 (Rutherford et al. 1986,1997) gives a run-off 1–10 
points, 1 being normal outfl ow and 10 meaning no outfl ow at all (blind loop). 
The predictive value of the run-off score is somewhat controversial. There are 
studies where this run-off score is a strong predictor of bypass outcome (Albäck 
et al. 1998, Biancari et al. 1999, Seeger et al. 1999). In contrast, studies by 
Plecha et al. (1993), Tordoir et al. (1993) and Takolander et al. (1995) found no 
effect of run-off score on graft patency. The explanation for this discrepancy 
between studies might be the limited accuracy of the Ad Hoc Committee’s run-
off score due to its dependency on the quality of angiography images. All in all, 
the assessment of angiographic scoring appears subjective, as illustrated by the 
problems in repeatability in such scoring methods (Kukkonen et al. 2010).
2.3.2 Type of conduit
The type of conduit is a major determinant of bypass outcome (Schanzer at al 
2009). An autologous vein is superior to prosthetic grafts as bypass material 
for infrainguinal reconstructions due to long-term patency and resistance to 
infections (Klinkert et al. 2004).
2.3.2.1 Vein grafts 
The great saphenous vein
Kunlin performed the fi rst bypass with an autologous saphenous vein in 1949 
(Kunlin 1951). A single- segment great saphenous vein (GSV) is the preferred 
graft for infrainguinal revascularizations in terms of long-term patency and 
limb salvage (Klinkert et al. 2004, Perreira et al. 2006). Excellent long-term 
results in a series of 2,058 patients undergoing infrainguinal in situ saphenous 
vein bypass (Indication was limb salvage in 91% of patients) were reported by 
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Shah et al. (1995).They reported 1-, 5- and 10-year secondary patency rates 
of 91%, 81 % and 70%, respectively. Leg salvage at one, fi ve and ten years 
was 97%, 95%, and 90%, respectively. The great saphenous vein is superior 
to prosthetic material in terms of patency even in an above-knee position 
(Johnson et al. 2000) and especially in infrapopliteal revascularizations 
(Bergan 1982, Veith 1986). Klinkert et al. (2004) reviewed 25 articles 
comparing the patency of femoral to above-knee popliteal saphenous vein 
against PTFE bypasses. They reported 2- and 5-year primary patency rates of 
81% and 69%, respectively, for venous bypasses, and for PTFE bypasses the 
adjacent rates wear 67% and 49%, respectively. When only randomized trials 
were considered, venous bypasses were again superior to PTFE bypasses at 
all intervals studied: the 2- and 5-year primary patency rates of venous versus 
PTFE bypasses were 80% vs. 69% and 74% vs. 39%, respectively. Since both 
randomized and retrospective studies comparing venous with PTFE bypasses 
showed that vein grafts were superior PTFE prostheses, the authors concluded 
that the saphenous vein should be used as graft material whenever it is 
available and of adequate quality. Therefore, it seems that a single-segment 
great saphenous vein is the conduit of choice in both supra- and infrapopliteal 
revascularizations for CLI. Table V summarizes randomised clinical trials 
comparing saphenous vein bypasses and PTFE bypasses.
Table V. Randomised clinical trials comparing vein conduit and PTFE prosthesis in infra-
inguinal bypasses
CLI % PATENCY p-value
Author, year (n)
2Y 4Y 5Y
Above-knee fem-pop
Klinkert 2003 (n=151)
GSV
PTFE
55
61
-
-
-
-
76%
52%
0.035
Johnson 2000 (n=752)
Vein 
PTFE
69
81%
69%
-
-
73%
39%
0.001
Veith 1986 (n=176)
GSV
PTFE
100
-
-
61%
38%
-
-
0.25
Below-knee fem-pop
Veith 1986 (n=153)
GSV
PTFE
100
-
-
76%
54%
-
-
<0.05
Infrapopliteal 
Veith 1986 (n=204)
GSV
PTFE
100
-
-
49%
12%
-
-
<0.001
CLI%=proportion of critical limb ischemia patients
GSV= great saphenous vein
PTFE= polytetrafl uoroethylene
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According to the randomized studies available, there seems to be no 
difference in patency regardless of whether the saphenous vein is used as a 
reversed conduit or in situ (Watelet et al. 1986, Wengerter et al. 1991, Harris 
et al. 1993, Watelet et al. 1997). All four of these studies demonstrated no 
difference in secondary patency between in situ and reversed saphenous vein 
bypasses (Table VI). 
Table VI. Patency of reversed versus in situ bypass 
Author (year) n Bypass type PATENCY
Reversed In-situ p-value
Watelet (1986) 100 AK/BK popliteal 88% 71% ns
Wengerter (1991) 125 infrapopliteal 67% 69% ns
Harris (1993) 215 AK/BK popliteal 77% 68% ns
Watelet (1997) 91 AK/BK popliteal 70% 65% ns
AK=above-knee
BK=below-knee
Alternative autologous veins
The great saphenous vein is evidently the best conduit for infrainguinal 
revascularizations due to its superior patency. Unfortunately, a great number 
of patients who would need a bypass procedure for limb salvage lack the GSV. 
This may be due to previous coronary artery bypass grafting, lower extremity 
bypasses or varicose vein surgery. Furthermore, even if not absent, the GSV 
can be unusable due to a too small calibre, varicosities or postphlebitic vein 
wall pathology. The usable ipsilateral GSV (IGSV) is reported to be absent 
in approximately 20%–45% of patients (Taylor et al. 1987, Holzenbein et al. 
1996, Chew et al. 2002). In these situations, the contralateral GSV (CGSV) 
can be used unless the donor limb is also critically ischaemic. If so, or if both 
the IGSV and CGSV are absent or of poor quality, other autologous conduit 
options are arm veins (basilic vein or cephalic vein) or the lesser saphenous 
vein (LSV). 
Arm veins
The fi rst bypass using arm veins, specifi cally the cephalic vein, as a conduit 
was described by Kakkar in 1969. Subsequently, clinical series over the past 
25 years have introduced good long-term results for arm vein bypasses, with 
patency and leg salvage rates at 3 years ranging from 40% to 73% and 63% 
to 92%, respectively (Andros et al. 1986, Balshi et al. 1989, Harvard et al. 
1992, Sesto et al. 1992, Flamme et al. 1995, Gentile et al. 1996, Tisi et al. 
1996, Holzenbein et al. 1996, Faries at al 2000a-c, Chew et al. 2001). Arm 
veins are relatively easy to harvest, and one advantage of using arm veins 
as conduit is the avoidance of possible surgical wound problems in donor 
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limbs and the preservation of the CGSV for subsequent contralateral limb 
revascularization or CABG. Therefore, some groups (Holzenbein et al. 1996, 
Faries et al. 2000a, c) have even introduced a policy of using arm veins as 
the fi rst alternative if the ipsilateral GSV is absent. In contrast, those who 
favour the use of the contralateral GSV fi rst can defend their policy based on 
reports where the need for subsequent contralateral limb revascularization is 
only 20%–23% (Stonebridge et al. 1991, Poletti et al. 1998). The need for 
subsequent CABG is even lower, 2%–3% within 5 years, as reported by Chew 
et al. (2002) and Poletti et al. (1998). The basilic vein or at least the cephalic 
vein is usually long enough for femoral-to-popliteal bypass or for popliteal-
to-distal bypass. However, in femorodistal bypasses, splicing is usually 
required. According to reports by Armstrong et al. (2004), spliced arm vein 
grafts were the most prone to stenosis development, whereas several other 
groups (Gentile et al. 1996, Holzenbein et al. 1996, Faries et al. 2000c, Chew 
et al. 2001) have demonstrated that splicing does not have an effect on the 
patency. An alternative for splicing in some cases where a longer vein graft is 
needed might be the use of a cephalic-basilic loop, a technique described by, 
for instance, Holzenbein and co-workers (1995).
Other autologous veins
The lesser saphenous vein (LSV) is also one graft option in the absence of the 
GSV. The fi rst reports using the LSV in infrainguinal bypass grafting were 
published by Shandall et al. (1987) and Weaver et al. (1987). The relative 
shortness of the LSV, however, limits its usability, but the LSV can be used 
as a part of spliced vein grafts if the calibre and quality is suffi cient. One 
solution for the shortness of the LSV is to use it in combination with its thigh 
extension, the vein of Giacomini, as introduced by Delis et al. (2004).
The results of using lesser saphenous vein grafts are sparse in the literature—
however, Belkin et al. (1995) published a series of 300 re-operations where 
34 grafts predominantly constructed from the LSV were used. The fi ve-year 
secondary patency and leg salvage rates were both 55% and the authors 
reported that the results with LSV grafts were equal to those of arm vein 
bypasses. Chang et al. (1992) achieved a 55% 3-year primary patency rate 
in a series of 69 LSV infrainguinal bypasses, 73% of which were secondary 
bypasses. 
In the absence of usable superfi cial veins, the femoral vein can also be used 
for bypass grafting. Schulman et al. (1986) published a series of 80 femoro-
popliteal bypasses using the deep veins of the leg as conduits, with rather 
good results; the 1-, 3- and 5-year patency rates were 89%, 70% and 60%, 
respectively. The morbidity, such as venous stasis or ulceration, related to 
deep vein harvesting was very low. Recently, Kaczynski and Gibbons (2011) 
reported on their series of 20 infrainguinal bypasses using femoral vein as a 
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conduit. At fi ve years, the primary, assisted primary and secondary patency 
rates were 36%, 66% and 78% respectively. Five-year limb salvage was 
83%. In this series as well, late venous morbidity was only mild or moderate, 
although temporary leg swelling after femoral vein harvesting was common. 
2.3.2.2 Prosthetic grafts
Despite the superior long-term patency and leg salvage rates of vein grafts, 
the use of a prosthetic graft may be necessary in patients with CLI and with 
no available autologous vein material. Approximately 20%–45% of patients 
with critical limb ischaemia lack a suitable saphenous vein. When secondary 
bypasses are performed, the rate of patients who have no suitable vein material 
is reported to be as high as 50% (Belkin et al. 1995). 
Prosthetic grafts, either expanded polytetrafl uoroethylene (ePTFE) or 
polyester (Dacron), are widely used for infrainguinal bypasses. Clinical series 
from 25 years ago (Sterpetti et al. 1985, Veith et al. 1986) report excellent 
patency and leg salvage rates for above-knee femoropopliteal bypasses. In a 
meta-analysis by Hunink et al. (1994), a 5-year primary patency of 47% for 
above-knee PTFE bypasses was reported. Expanded polytetrafl uoroethylene 
has been the most popular and widely used prosthetic material; however, 
several studies ten years ago demonstrated that in above-knee femoropopliteal 
bypasses, polyester and ePTFE are equal in terms of patency (Robinsson et 
al. 1999, Green et al. 2000, Post et al. 2000). Furthermore, a more recent 
randomized study (Jensen et al. 2007) concluded that polyester is at least as 
good or even better and more durable than ePTFE for above-knee bypasses. 
A Cochraine review (Mamode and Scott 2000) of nine trials including 1,334 
patients reported no difference between ePTFE and Dacron. According to 
Gupta and co-workers (1991), ring-support does not affect the patency of 
ePTFE bypasses in the femoro-popliteal (above- or below-knee) position.
Although widely accepted in above-knee bypasses where the outfl ow is 
usually rather good, the use of prosthetic material in infrapopliteal bypasses 
is controversial. Prosthetic material is more thrombogenic than an autologous 
vein graft, especially in low-fl ow circumstances, and, mainly due to this aspect, 
the results of infrapopliteal prosthetic bypasses have been disappointing or 
only moderate. A meta-analysis of PTFE infrapopliteal bypasses published by 
Albers et al. (2003) yielded pooled 3-year primary patency, secondary patency 
and limb salvage rates of 41%, 51% and 66%, respectively. The pooled 
weighted data for 1-, 3- and 5-year primary patency rates of 70%, 35%, and 
25%, respectively, for femorodistal prosthetic bypass are reported in TASC II 
(Norgren et al. 2007).
Prosthetic grafts tend to occlude especially during the fi rst months after 
bypass (Devine et al. 2006). This has probably been the most important reason 
Arvela_vk3.indd   30 14.10.2011   09:06:00
31
REVIEW OF THE LITERATURE
for the development of technical improvements, such as heparin coatings and 
anastomotic modifi cations (pre-cuffed prostheses). Indeed, heparin coating 
seems to have improved at least the short-term results of not only femoro-
popliteal, but also infrapopliteal prosthetic bypasses. In the past fi ve years, 
one-year primary and secondary patency rates for femoropopliteal bypasses 
using heparin-bonded prostheses are reported to range from 78% to 84% and 
from 89% to 96%, respectively. For infrapopliteal bypasses, the corresponding 
rates are 74%–75% and 85%–100%, respectively (Bosiers et al. 2006, Peeters 
et al. 2006, Scharn et al. 2008). A recent Scandinavian, randomised multicentre 
trial showed, that heparin coating was associated with signifi cant graft failure 
reduction compared to average ePTFE, especially in femoro-popliteal bypasses 
for CLI, where graft failure reduction was reported to be 50% (Lindtholt et 
al. 2011). 
A vein cuff is suggested to improve prosthetic bypass patency especially at 
the infrapopliteal position. The Joint Vascular Research Group (JVRG) of the 
UK has published two series demonstrating the benefi cial effect of a vein cuff 
on patency. The fi rst series reported improved patency and a trend towards 
better limb salvage in below-knee bypasses (Stonebridge et al. 1997). In the 
latter randomised controlled trial, Griffi ths et al. (2004) reported higher 3-year 
patency rates for Miller vein cuff vs. non-cuff in below-knee femoro-popliteal 
bypasses. In contrast, a recent randomised Scandinavian Miller Collar Study 
(SCAMICOS 2011) failed to demonstrate any infl uence of a vein cuff on 
patency or leg salvage in below-the knee bypasses for CLI. Furthermore, 
a concomitant AV fi stula has been introduced to improve prosthetic bypass 
patency, but no major additional benefi t has been demonstrated (Laurila et al. 
2004).
2.3.3 Quality of vein graft
The quality of the vein graft as a determinant of graft patency has been 
demonstrated in several studies—fi rst decades ago by Szilagyi et al. in 
1973 and LoGerfo et al. in 1977 and later by others (Pannetta et al. 1992, 
Wilson et al. 1996). Saphenous veins are reported to have several pre-existing 
pathological conditions, such as increased wall thickness, postphlebitic 
changes and varicosities, which may predispose to graft failure. The incidence 
of such saphenous vein “disease” and subsequent unsuitability for bypass 
grafting is reported to be 2%–12% (Panetta et al. 1992). The aetiology of the 
venous diseases seems to be multifactorial in origin, and, in addition to a gross 
morphological appearance of vein, there is no clear indicator to identify those 
veins which should be rejected as grafts (Pannetta et al. 1992, Varty et al. 1993). 
Miller et al. (1990) described the presence of intraluminal webs and bands 
as signs of incomplete recanalisation after thrombophlebitis in angioscopic 
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evaluations of vein grafts. Wilson and co-workers (1996) published a series of 
52 vein bypasses, 38 of which included angioscopy for the detection of vein 
abnormalities. The angioscopic fi ndings included intraluminal strands and 
fi brotic webs, bands, thrombi and haemorrhagic mural plaques. Most of these 
abnormalities were not detected in preoperative duplex scanning. Similarly, 
Pannetta and colleagues (1992) reported that duplex failed to identify as many 
as 38% of the abnormal veins. Davies et al. (1993) histologically studied 
veins used for bypass and concluded that signifi cant pathological changes, 
such as intimal thickening and histological evidence of early atheromatous 
changes in the intima, are seen in long saphenous and cephalic veins which 
are considered normal. However, the effect of pre-existing intimal thickening 
alone on later graft stenosis development is controversial, as there are reports 
questioning the association between pre-existing vein wall thickness and later 
vein graft stenosis development. Varty et al. (1996) reported no difference in 
either intimal or medial thickness between stenosed and non-stenosed grafts. 
Varicosity is usually considered a contraindication to autologous vein 
bypass grafting due to increased formation of intimal hyperplasia, the risk of 
aneurysm formation and even subsequent graft rupture. Varicotic dilatation 
may involve the entire saphenous vein or just an isolated segment.
Cephalic and basilic veins are often thin walled which may predispose 
them to ectatic dilatation in the long term. Arm vein grafts are especially 
prone to stenosis development and aneurysm formation (Armstrong et al. 
2004). Moreover, Armstrong et al. (2004) reported the incidence of vein 
graft abnormalities in arm vein bypasses to be as high as 55% and, similarly, 
Maraccaio et al. (1993) also reported a high incidence of vein graft disease 
among arm veins. 
2.3.4 Size of vein graft
Not only the quality, but also the adequate size of the vein graft is a major 
determinant of graft patency. Several studies have demonstrated that a 
small calibre of the vein graft is an independent risk factor for vein graft 
failure (Towne et al. 1989, Varty et al. 1993, Idu et al. 1999). A small GSV is 
associated with a twofold risk of early failure (Schanzer et al. 2007). Several 
factors are suggested as an explanation for the increased risk of failure in vein 
grafts of less than 3.5 mm. The calibre of the vein may be small because of 
wall thickness, some other vein wall abnormality or as a result of previous 
phlebitis. Furthermore, small-calibre veins may be more prone to damage 
during vein harvest, dilatation and valve lysis (Panetta 1992, Marin 1993). 
Idu et al. (1999) suggested that a small calibre is a greater risk factor for graft 
failure than the use of arm or composite vein grafts and that these alternative 
veins should be preferred if the GSV is less than 3.5 mm in diameter. 
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Observations from a large multicentre trial suggest that vein graft type and 
size are major factors affecting the outcome of infrainguinal bypass grafts 
(Schanzer at al 2007).
2.3.5 Adjunctive methods for poor-quality vein grafts
Poor-quality vein grafts are prone to stenosis development and subsequent 
graft occlusion. The application of external support has been proposed to 
allow the use of suboptimal-quality veins otherwise unacceptable for bypass 
grafting. External scaffolding is supposed to stabilise the vein, minimise the 
arterial stress and thus reduce the rate of stenosis development, therefore 
improving graft patency. Preclinical animal studies employing external 
support of suboptimal-quality vein bypasses have shown a less pronounced 
neointima formation, with subsequently improved long-term patency rates 
compared to unsupported grafts (Bambang et al. 1997, Dashwood et al. 
2002, Vijayan et al. 2002, Jeremy et al. 2004). The use of external polyester 
reinforcement of a vein graft was fi rst introduced in clinical use by Parsonet 
and Shah (1963). Later, several small clinical series (Bednarkiwicz et al. 1998, 
Souyry et al. 1999, Moritz et al. 1992 and 1993) have reported the use of both 
polytetrafl uoroethylene (PTFE) and polyester prosthetic reinforcement of 
varicose vein grafts, with acceptable results. Melliere et al. (1995) published a 
small series of patients with critical limb ischaemia undergoing bypass, where 
dilated segments of greater saphenous veins were wrapped in short segments 
of PTFE prosthesis or polyester mesh. Neufang et al. (2003) reported over 80% 
1-year secondary patency rates for infrainguinal bypasses using varicotic vein 
grafts reinforced with PTFE. According to a more recent report by Melliere 
and colleagues (2007), patency rates using varicotic vein grafts with prosthetic 
reinforcement were higher than those achieved using prosthetic grafts. 
2.3.6 Vein graft failure
The pattern of infrainguinal vein graft failure has remained largely similar 
since the report by Darling and Linton (1972) nearly three decades ago. Vein 
graft failure can be divided into three phases, depending on the timing of 
failure: early (<30 days), intermediate (30 days–2 years) and late (>2 years).
Early failures are usually due to technical mistakes, such as poorly 
constructed anastomosis, insuffi cient infl ow or outfl ow, retained venous 
valves, or a poor-quality vein. Any of these reasons can reduce graft fl ow 
below the thrombotic threshold velocity, with subsequent graft occlusion. In 
addition to fl ow, the other elements of the Virchow triad—endothelial damage 
and hypercoaguable states—may cause early vein graft failure (Monahan and 
Owens 2009).
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Intermediate vein graft failure is due to intimal hyperplasia. Carrel and 
Guthrie (1906) described this phenomenon more than a hundred years ago. As 
a response to the arterialization of the vein graft and surgical trauma, vascular 
smooth muscle cells (SMSs) migrate from the media to the intima and switch 
phenotype to a more proliferative form (Cox et al. 1991, Davies and Hagen 
1995), which leads to a production of excessive amounts of extracellular 
matrix and subsequent intimal hyperplasia. All vein grafts probably undergo 
some degree of intimal hyperplasia. However, it remains partly unclear why 
some vein grafts are affected more than others (Landry et al. 2002). Twenty 
to twenty-fi ve percent of infrainguinal vein grafts develop signifi cant stenosis 
during the fi rst postoperative year due to intimal hyperplasia (Szilagyi et al. 
1973, Sladen et al. 1981, Whittemore et al. 1981, Grigg et al. 1988, Wilson et 
al. 1996). These stenoses are usually asymptomatic and, if not corrected, may 
limit the graft fl ow and lead to subsequent graft thrombosis (Idu et al. 1999).
Late vein graft failure (after 2 years) is commonly attributed to dyslipidaemia 
and the progression of atherosclerosis, compromising either infl ow or outfl ow 
vessels. The progression of atherosclerosis can also directly affect the vein 
graft itself, as described in regard to saphenous grafts in coronary artery 
bypass grafting (Motwani and Topol 1989) and in lower extremity bypass 
grafting (DeWeese and Rob 1977, Reifsnyder et al. 1993).
According to Monahan and Owens (2009), patient-related risk factors 
predisposing to vein graft stenosis development are different from 
traditional cardiovascular risk factors (Table VII). The early presentation of 
atherosclerosis is considered as a somewhat different, more virulent form than 
that which occurs in older patients (Aronson 1989, Harris et al. 1996, Levy 
1996). Young age can thus be considered a risk factor for vein graft failure. 
Elevated C-reactive protein (CRP) seems to be a risk factor for vein graft 
failure. Hispanics and African Americans have elevated levels of CRP, which 
might explain why they have an increased risk of vein graft failure. Moreover, 
Monahan and Owens (2009) speculated that many of the other observed 
risk factors, such as a redo operation and CLI as an indication, can also be 
considered as increased infl ammatory states. This might explain the fi nding 
that statin use seems to reduce graft stenosis development (Porter and Turner 
2002). Smoking is not only a risk factor for atherosclerosis, but, it also has 
adverse effect on graft patency due to endothelial dysfunction and impaired 
nitric-oxide-mediated vasodilatation (Higman et al. 1993, 1996).
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Table VII. Patient-related risk factors for vein graft failure (Monahan and Owens 2009).
EARLY FAILURE INTERMEDIATE FAILURE LATE FAILURE
young age
hypercoaguable state
African American ethnicity
young age
hypercoaguable state
redo bypass
CLI as indication
smoking
African American or Hispanic 
ethnicity
infl ammation
dyslipidaemia
2.3.7 Vein graft surveillance
Despite surveillance, 10%–20% of vein grafts within the fi rst year and up to 
25% within 3 years after bypass will fail (Idu et al. 1988 and 1992, Bandyk et 
al. 1989, Bergamini et al. 1995, Lundell et al. 1995). As the graft salvage after 
occlusion is poor, with 2-year patency rates as low as 19%–31% (Seabrook 
et al. 1991, Hye et al. 1994, Nackman et al. 1997, Robinsson et al. 1997), the 
identifi cation and revision of signifi cant stenoses prior to graft occlusion is 
crucial. There is data suggesting that grafts can fail with no warning signs, 
and the positive predictive value of the ankle-brachial index (ABI) alone in 
detecting a failing graft is only 12%–34% (Bandyk 1990). Stenoses can be 
easily detected with ultrasonography, which is, however, time-consuming and 
expensive. The effi cacy and cost-effectiveness of intensive vein graft duplex 
surveillance is still controversial to some extent. It has been estimated that to 
be cost-effective, a surveillance programme should improve limb salvage rate 
by approximately 5% (Chesire and Wolfe 1993). The latest TASC consensus 
document suggests routine surveillance of vein grafts but does not recommend 
duplex scanning (Norgren et al. 2007). There are few randomised controlled 
trials assessing the effi cacy of duplex surveillance. Lundel et al. (1995) studied 
both vein graft and prosthetic bypasses and reported a better identifi cation of 
failing vein grafts by intensive duplex surveillance, which led to signifi cantly 
better assisted primary and secondary patency rates when compared to clinical 
surveillance. However, leg salvage rates did not differ between the groups. 
Ihlberg et al. (1998), on the other hand, failed to demonstrate any difference 
in assisted primary patency, secondary patency or limb salvage rates between 
the duplex and clinical surveillance groups in their series of 185 consecutive 
vein grafts. In a large multicentre trial published by Davies et al. (2005), 
594 patients were randomised to either clinical (n= 290) or duplex (n=304) 
surveillance. More graft stenoses were detected in the clinical surveillance 
group, but primary, assisted primary or secondary patency rates did not differ 
between the groups. 
Tinder et al. (2008) assessed the characteristics of graft failure to fi nd those 
Arvela_vk3.indd   35 14.10.2011   09:06:00
36
grafts that would most benefi t from intensive duplex surveillance. They found 
that warfarin therapy, a non-single-segment saphenous vein conduit and redo 
bypass were predictive for stenosis development. There is also data suggesting 
that risk grafts, such as arm vein grafts prone to stenosis development, benefi t 
signifi cantly from duplex surveillance. Armstrong et al. (2004) reported 
that duplex surveillance revealed graft stenosis in almost half of the study 
population, which resulted in a 48% graft revision rate. An excellent 3-year 
assisted primary patency rate of 91% was achieved due to effi cient duplex 
surveillance and early correction of detected stenoses.
According to the literature, there is no clear evidence to date supporting 
duplex surveillance of prosthetic grafts (Lundel et al. 1995, Hobollah et 
al. 1997). The mechanism of failure of prosthetic grafts is believed to be 
anastomotic stenosis and subsequent low graft fl ow. These anastomotic 
stenoses would be easily detected with duplex, but evidence of its cost-
effectiveness is lacking. According to Brumberg et al. (2007), early duplex 
scanning of infrapopliteal prosthetic grafts might, however, be reasonable—
not for detecting stenoses but for identifying low-fl ow grafts predisposing to 
thrombosis, thereby selecting patients for anticoagulation.
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AIMS OF THE PRESENT STUDY
The purpose of this study was to assess the results and outcome of infrainguinal 
bypasses for critical limb ischaemia, especially in high-risk patients or in cases 
of non-optimal vein grafts. The primary aim was to evaluate those patient- and 
graft-related factors that negatively affect the outcome and thereby to fi nd 
patients whose benefi t from infrainguinal bypass is remarkably limited. This 
knowledge could be useful in clinical decision-making, treatment modality 
and patient selection as well as resource allocation. The specifi c aims were to 
assess:
1. The effect of renal insuffi ciency on outcome and to evaluate the usefulness 
of estimated glomerular fi ltration rate (eGFR) in predicting poor outcome 
after infrainguinal bypass (I)
2. The effect of age on outcome and the results of surgical versus endovascular 
revascularization in patients ≥ 80 years of age with critical limb ischaemia (II)
3. The usefulness and accuracy of specifi c risk scoring methods (III)
4. Predictors of extremely dismal survival to aid in determining when not to 
perform bypass (I–IV)
5. The results of alternative autologous vein graft bypasses, the risk factors for 
graft failure and the rate of graft revision procedures (IV)
6. The outcome of high-risk patients undergoing infrainguinal bypass with a 
risk graft (IV)
7. The results of arm vein conduits in comparison to prosthetic grafts when an 
optimal vein graft is not available (V)
8. The feasibility of external polyester mesh scaffolding of compromised 
quality vein grafts (VI)
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MATERIAL AND METHODS
All retrospective studies (I–V) were approved by the Institutional Review 
Board of Helsinki University Central Hospital (HUCH). For a prospective, 
multicentre feasibility trial (VI), the approval of the Ethics Committee was 
obtained. 
1 PATIENTS AND STUDY DESIGNS
Study I is a retrospective single-centre cohort study of 603 consecutive patients 
who underwent infrainguinal bypass for critical limb ischaemia between 2002 
and 2005 at Helsinki University Central Hospital (HUCH). The purpose was 
to evaluate the effect of renal insuffi ciency on outcome and to compare serum 
creatinine and estimated glomerulal fi ltration rate as predictors of outcome. 
The main outcome endpoint was amputation-free survival. 
Study II is a retrospective single-centre cohort study of 584 patients aged at 
least 80 years who underwent infrainguinal endovascular (n= 277) or surgical 
(n=307) revascularization for critical limb ischaemia between 2000 and 2007. 
The purpose was to compare the results of PTA and bypass in octogenarians 
with CLI. Ninety-fi ve propensity-score-matched pairs were created to 
minimize the effect of confounding factors. Classifi cation and regression tree 
analysis were performed to further verify the effect of treatment modality on 
outcome. The main outcome endpoints were one-year survival, leg salvage 
and amputation-free survival. 
Study III is a retrospective cohort study from a single centre, and it 
includes 1,425 patients with CLI who underwent infrainguinal surgical 
(47.6%) or endovascular (52.4%) revascularization between 2000 and 2007 
at HUCH. The aim was to evaluate the Finnvasc score and Prevent III score 
as predictors of outcome. In order to assess the accuracy of these scoring 
methods in predicting intermediate outcome, they were tested by the receiver 
operating characteristic (ROC) curve. The main outcome end points were leg 
salvage, overall survival and amputation-free survival. 
Study IV is a retrospective cohort study from a single centre. All 
infrainguinal, autologous vein bypasses for CLI between 2000 and 2007 
(n=1109) at HUCH were included. The aim was to assess and to compare 
the outcome of bypasses with different types of vein grafts and to assess risk 
factors for vein graft stenosis and vein graft failure. The outcome endpoints 
of interest were primary, assisted primary and secondary patency. Subgroup 
analysis of high-risk patients with a risk graft was performed. 
Study V is a retrospective cohort study. A total of 290 consecutive 
infrainguinal bypasses for CLI using an arm vein conduit (n =130) or prosthetic 
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graft (n = 160) between January 2000 and December 2006 in a single centre 
(HUCH) were analysed. The outcomes of arm vein grafts and prosthetic grafts 
were compared in terms of primary, assisted primary and secondary patency. 
Leg salvage was also assessed. 
Study VI is a prospective, multicentre observational feasibility study of 50 
patients. The patient inclusion period was from May 2005 to March 2008. The 
participating centres were:
1. Helsinki University Central Hospital, Finland (20 patients)
2. Johannes Gutenberg University Hospital Mainz, Germany (13 patients)
3. J.W.Goethe University Hospital, Frankfurt, Germany (12 patients)
4. Municipal Hospital Muehldorf, Germany (three patients)
5. Verbundkrankenhaus Bernkastel/Wittlich, Wittlich, Germany (one patient) 
6. Kath. Kliniken Essen-Nord, Essen, Germany (one patient)
The aim of this study was to evaluate the feasibility of external polyester 
scaffolding in infrainguinal bypass grafting when the available vein material 
is suboptimal due to varicosity or dilatation. The primary objectives were 
short-term primary patency, assisted primary patency and secondary patency. 
Secondary objectives were to assess the rate of graft stenoses, infections and 
possible other adverse effects related to the use of external scaffolding. 
Demographic data of all patients included in all the studies is presented 
in Table VIII. The fl ow chart for patients in Studies I–V is shown in Figure 3.
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Table VIII. Demographic data of patients in studies I-VI.
Demographics STUDY I STUDY II
PTA                          bypass 
STUDY III STUDY IV STUDY V STUDY VI
number of patients 603 277                         307 1425 1109 290 50
age( years) 73 (65–80)* 86 (±4.0)**            85 (±3.7)** 73 (±11.7) 74 (36-107)* 74 (41–95)* 72 (39–93)*
eGFR (ml/min/1.73 m2)
SCr (μmol/l)
67 (46–89)*
86 (86–117)*
58  (±21)**            62 (±23)**  
n.a.                          n.a.               
66 (±34)**
n.a.
66 (4-99)*
87 (29-1161)*
n.a.
89 (40-999)*
n.a.
n.a.
follow-up time (months) 5 (0–46)* 24 (0-49)*              24 (0-49)* 29 (0-95)* 37 (0-121)* 35 (0-118)* 6
male sex 330 (55%) 77 (28%)                99 (32%) 707 (49%) 643 (58%) 122 (42%) 34 (68%)
CAD 359 (63%) 196 (71%)             227 (74%) 909 (64%) 691 (62%) 691 (62%) 24 (48%)
diabetes 276 (47%) 143 (52%)             114 (37%) 819 (58%) 548 (49%) 113 (39%) 21 (42%)
hypertension 397 (68%) 212 (77%)             236 (77%) 1077 (76%) 785 (71%) 218 (75%) 40 (80%)
hyperlipidaemia 229 (48%) 75 (27%)                85 (27%) 584 (41%) 440 (40%) 126 (44%) 27 (54%)
COPD 111 (19%) n.a. 215 (15%) 152 (14%) 51 (18%) n.a.
CVD 116 (20%) 61 (22%)               40 (13%) 277 (20%) 199 (18%) 44 (15%) n.a.
current smoking 173 (30%) 19 (7%)                 20 (7%) n.a. 302 (27%) 74 (26%) 13 (26%)
CLI % 
(FIII/FIV)%
100
(40/60)
100                        100
(17/83)                 (29/71)
100
(21/79)
100
(32/68)
100
(41/59)
64
(12/52)
* median (range), ** mean (±SD)
CAD=coronary artery disease 
COPD= chronic obstructive pulmonary disease
CVD = cerebrovascular disease
CLI%=proportion of critical limb iscemia patients
FIII= Fontaine class III (ischaemic rest pain)
FIV= Fontaine class IV (ulcer/gangrene)
n.a.= not available/not assessed
Figure 3. Flow chart of the study populations (studies I–V)
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2 INVESTIGATIONAL PRODUCT (VI) 
The polyester mesh tube (ProVena®, B. Braun Aesculap, Germany) is 
manufactured from multifi lament polyester yarn (polyethylene terephthalate). 
It is supplied in various diameters and lengths. ProVena® is a porous prosthesis 
with a honeycomb-like structure, and it is designed for the intra-operative 
external scaffolding of autologous veins of non-optimal quality due to 
varicosities or ectatic dilatation. 
3 METHODS
3.1 Data collection and validation
All the retrospective studies (I–V) are registry-based studies. Data were 
collected prospectively into our institutional database of surgical and 
endovascular revascularizations (Husvasc) and scrutinized retrospectively. 
The registry includes patient demographics, comorbid conditions, indications 
for surgery, specifi c operative details, complications and outcome at discharge. 
Follow-up data includes graft patency and dates of any graft revisions or graft 
occlusion as well as the dates of major amputation or death. Registry data of 
all patients included in the study were cross-checked against patient records, 
and any missing data in the registry was retrieved from the patient’s records 
and completed in registry. The dates of death were retrieved from the Finnish 
national population registry, Statistics Finland. Data on late amputations have 
been completed retrospectively from the fi les of the National Institute for 
Health and Welfare.
For the prospective, multicentre pilot study (VI), clinical data were collected 
at the time of patient enrolment, at the time of the procedure, at discharge and 
at planned follow-up visits. Data were collected using patient record forms. 
Data from all six participating centres from two countries were combined and 
analysed.
3.2 Estimation of renal function (I, II, III)
Serum creatinine levels were measured using the IDMS (isotope dilution-
mass spectrometry) traceable enzymatic assay (Roche Diagnostics, Basel, 
Switzerland). Glomerular fi ltration rate was estimated using the 4-variable 
Modifi cation of Diet in Renal Disease (MDRD) Study equation for creatinine 
results traceable to an IDMS method: eGFR (mL/min/1.73 m2) =175 x 
(Scr/88.4)-1.154 x (Age)-0.203 x 0.742 (if female) x 1.210 (if African American) 
(SI units) (Peake and Whiting 2006, Levey et al. 2005 and 2006). Chronic 
kidney disease (CKD) is divided into fi ve stages according to The National 
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Kidney Foundation – Kidney Disease Outcomes Quality Initiative (NKF 
KDOQI) guidelines. Stages 1 and 2 as well as stages 4 and 5 were summed up 
to establish three categories (Table IX).
Table IX. Staging of renal insuffi  ciency according to the National Kidney Foundation 
– Kidney Disease Outcomes Quality Initiative (NKF KDOQI) guidelines and our 
modifi cation.
Stage eGFR Description (NKF KDOQI) Our modifi cation 
1 90 Normal renal function > 60 no or mild insuffi  ciency
2 60–89 Mild renal insuffi  ciency
3 30–59 Moderate renal insuffi  ciency  30–60 moderate renal insuffi  ciency
4 15–29 Severe renal insuffi  ciency < 30 severe renal insuffi  ciency or
renal failure5 <15 End-stage renal disease (uraemia)
3.3 Risk score assessment (III)
As Biancari et al. (2007) demonstrated, diabetes, coronary artery disease, 
foot gangrene and urgent operation were independent predictors of 30-day 
postoperative mortality and/or major lower-limb amputation. Therefore, the 
Finnvasc scoring method was developed by assigning 1 point each to these 
four risk factors. 
In a modifi ed version of the PIII score, published by Schantzer et al. 
(2009), points were assigned to the presence of dialysis (4 points), tissue loss 
(3 points), age >75 years (2 points) and coronary artery disease (1 point). The 
sum total of points was converted to a score which places the patient in the 
low- (score < 3), medium- (score 4–7) or high-risk (score> 8) category. We 
did not have the information of the number of patients on dialysis—therefore, 
for the calculation of the modifi ed PIII score, dialysis was categorized as CKD 
class 5 (eGFR <15ml/min/1.73m2) because it appropriately includes patients 
with the most severe degree of renal failure (Levey et al. 2003).
3.4 Revascularization procedure
The suitability of infl ow and outfl ow vessels for bypass was evaluated by means 
of magnetic resonance angiography (MRA), conventional digital subtraction 
angiography (DSA) or computed tomography angiography (CTA). In Studies 
II–III, the angiograms were evaluated retrospectively and the runoff score was 
calculated using the grading scheme proposed by Rutherford and co-workers 
(1997).
The size and quality of usable vein material was preoperatively mapped 
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with ultrasonography. Autologous vein grafts were used whenever possible. 
The best available vein graft to treat the immediate problem was preferred. 
Therefore, in the absence of the ipsilateral great saphenous vein (IGSV), the 
contralateral great saphenous vein (CGSV) was the preferred conduit unless 
the donor limb was ischaemic. Arm veins or the lesser saphenous vein were 
used if a usable GSV was absent. The operating surgeon decided whether the 
vein graft was to be used in a reversed or non-reversed position. If a spliced 
vein graft was needed, vein segments were employed in a reversed or non-
reversed position to minimize size mismatch of vein-to-vein anastomoses and 
artery-to-vein anastomoses. The vein-to-vein anastomoses were sutured with 
7-0 interrupted sutures. 
A prosthetic graft, either expanded polytetrafl uoroethylene (ePTFE) or 
polyester (Dacron) was applied if usable autologous veins were completely 
unavailable. In prosthetic bypasses to infrapopliteal arteries an adjunctive 
vein cuff, either Miller cuff (Miller 1984; Figure 4.) or St. Mary’s boot (Tyrrel 
and Wolfe 1991; Figure 4.) was used, except in cases where precuffed ePTFE 
prosthesis was used.
Figure 4. An illustration of distal anastomosis of prosthetic bypass without vein cuff  
(above), with Miller cuff  (middle) and with St. Mary’s boot (below).
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In Study VI, polyester mesh (Provena®) was used as external support for 
vein grafts. Prior to suturing the anastomoses, an appropriate length of 
polyester mesh tube was drawn over the vein graft with a special instrument. 
Fibrin glue was used to fi x the mesh to the outer layer of the vein graft to 
facilitate anastomosis suturing if the mesh tube was extended to cover the 
anastomoses.
Studies II and III also include endovascular revascularizations for CLI. 
They were performed mostly by interventional radiologists. The technique 
was mainly intraluminal, and subintimal angioplasty was used only in a 
minority of cases. Drug-eluding balloons were not applied, and stents were 
not used routinely but were employed selectively for long occlusion or in 
cases of target lesion dissection. 
Transit time fl ow measurement was used to ensure adequate graft fl ow (mL/
min) perioperatively. The measurements were performed with a transit time 
fl owmeter (CardioMed CM4006; Medistim A/S, Oslo, Norway), which is based 
on an ultrasonic pulsed-beam technique. The idea is to measure volume fl ow 
within the conduit. A precalibrated probe of the correct size to fi t the vein graft 
is placed around the conduit to measure the fl ow. In the case of compromised 
graft fl ow, intraoperative duplex scanning was performed to exclude vein 
wall abnormalities and technical defects in anastomoses. Angioscopy or 
intraoperative angiography was used only selectively. The threshold criteria 
for duplex or angiography were the following: for femoropopliteal grafts, rest 
fl ow <150 mL/min; for crural bypasses, rest fl ow <50 mL/min or maximum 
fl ow capacity (fl ow after injection of 40 mg papaverine) <110 mL/min; and for 
pedal reconstructions, maximum fl ow capacity <45 mL/min.
Intraoperative heparin was administered to all patients according to weight, 
and the adequacy of heparinization was controlled using activated clotting 
time (ACT) assessment. At the end of the procedure, if needed, prothamine 
sulphate was administered to antagonize the heparin. All patients received 
weight-adjusted doses of low-molecular-weight heparin (LMWH) twice a 
day postoperatively until discharge and ASA 100 mg per day indefi nitely if 
there were no contraindications. Some patients received clopidogrel instead of 
aspirin (aspirin allergy, previous coronary balloon angioplasty, etc.). Warfarin 
was used only if there was a clear indication (atrial fi brillation, trombofi lia, 
etc.) for it.
3.5 Follow-up
In all studies, the follow-up protocol was similar. The follow-up visits were 
carried out routinely at 1, 6 and 12 months postoperatively and thereafter 
annually. The evaluation protocol included the inspection of limb status, 
pulse palpation and the measurement of ankle-brachial indices (ABI) and 
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toe pressures (TP). For vein grafts, duplex scanning of the entire graft, 
anastomoses as well as infl ow and outfl ow arteries was performed. If duplex 
scanning revealed signifi cant focal stenosis (peak systolic velocity ratio [Vr] 
≥3, peak systolic velocity [PSV] over 300 cm/s or overall graft velocity <45 
cm/s in a normal-calibre graft), angiography was performed. The patency of 
a prosthetic graft was ensured by ABI and TP measurements and Doppler 
auscultation. The graft was considered patent if ABI remained improved 
(>0.15) in comparison to the preoperative value and the Doppler fl ow signal 
from at least two points over the graft was audible. The duplex scanning of 
prosthetic bypass was performed only if the patency was uncertain.
The clinical follow-up after endovascular procedures was similar, but 
duplex scanning or DSA was performed only if foot status was worsening or 
there was otherwise a suspicion of target lesion re-stenosis or occlusion.
3.6 Defi nition of outcome endpoints
In all studies (I–VI), the terms survival, leg salvage and amputation-free 
survival as well as the criteria for patency and the defi nitions of primary, 
assisted primary and secondary patency are as recommended by the revised 
Ad Hoc Committee on Reporting Standards, SVS/NA-ISCVS (Rutherford et 
al. 1997).
3.7 Statistical methods 
Statistical analyses were performed using SPSS for Windows, versions 13.0 
(I), 15.0 (II-III), 16.0 (VI), 17.0 (V) and 19.0 (IV) (SPSS Inc., Chicago, IL, 
USA).
Comparisons between the SCr and eGFR groups were made using the 
Kruskal-Wallis test for continuous variables and Chi-squared test for categorical 
variables (I). In Studies II–V, Pearson’s Chi-square test and Fisher’s exact test 
(if n<5) were used for analyses of categorical data; non-parametric variables 
were analysed with the Mann-Whitney test. 
Patency rates (IV–VI), leg salvage (I–V), survival (I–IV) and amputation-
free survival (I–IV) were estimated using the Kaplan-Meier method, and 
comparisons between curves were performed with the aid of the Mantel-Cox 
log rank test.
Crude and adjusted hazard ratios (HRs) with 95% confi dence intervals 
(CIs) of mortality, limb loss and amputation and/or death were calculated for 
both eGFR and creatinine using Cox regression analysis (I). 
The propensity score (the risk of a patient to be included in either the 
PTA or the bypass group) was calculated by means of logistic regression. 
Variables with a p value of less than 0.2 in univariate analysis were included 
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in the regression model. Hosmer-Lemenshow’s test was used to assess the 
regression model fi t. Receiver operating characteristics (ROC) curve analysis 
was applied to estimate the area under the curve of the model, predicting the 
probability of being included in the PTA or bypass group. Areas under the 
curve (AUC) were calculated with 95% CIs. Propensity score was used for 
one-to-one matching as well as to adjust for other variables in estimating their 
impact on the postoperative outcome on multivariable analysis. Classifi cation 
and regression tree (CART) analysis was employed to identify independent 
risk factors for 1-year AFS and to even further verify the impact of treatment 
method on outcome (II).
The ROC curve analysis was used to estimate the predictive value of 
the Finnvasc and PIII risk scoring methods in predicting 30-day and 1-year 
amputation-free survival. Cox regression analysis was applied to adjust these 
risk scores for the anatomic level of revascularization and type (endovascular 
vs. bypass) of revascularization (III).
A p value of <0.05 was considered statistically signifi cant.
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RESULTS
1 RENAL INSUFFICIENCY AS AN INDEPENDENT 
PREDICTOR OF POOR AMPUTATION-FREE SURVIVAL (I)
If estimated GFR was used, 40% of the study population was found to have 
some degree of renal insuffi ciency. When the upper level of normal serum 
creatinine level alone was used as a criterion, only 23% of patients had 
impaired renal function.
Severe renal insuffi ciency (eGFR<30 or SCr >200) was an independent 
predictor of poor survival, leg salvage and amputation-free survival. Moderate 
renal insuffi ciency was also associated with an approximately 2-fold risk of 
death, amputation or amputation/death (Table X).
Table X. Adjusted hazard ratios (HR) with corresponding 95% CIs of impaired survival, 
leg salvage and amputation-free survival in diff erent eGFR and SCr categories. 
HR (95% CI)* p-value
Survival
eGFR 30–60 1.87 (1.22–2.87) 0.004
eGFR <30 4.05 (2.22–7.39) <0.0001
Scr 120–200 2.18 (1.33–3.59) 0.002
Scr >200 3.53 (1.82–6.84) <0.0001
Leg salvage
eGFR 30–60 1.61 (0.78–3.35) 0.199
eGFR <30 6.51 (2.71–15.59) <0.0001
Scr 120–200 2.27 (1.01–5.13) 0.048
Scr >200 6.20 (2.47–15.56) <0.0001
Amputation-free survival
eGFR 30–60 1.66 (1.12–2.47) 0.012
eGFR <30 3.99 (2.40–6.63) <0.0001
Scr 120–200 1.82 (1.16–2.85) 0.010
Scr >200 3.56 (2.03–6.25) <0.0001
*HRs are relative to the baseline renal groups of eGFR >60 or SCr< 120
Kaplan-Meier estimates of amputation-free survival showed that according 
to eGFR, both severe and moderate renal insuffi ciency were associated with 
decreased AFS when compared to normal eGFR (Figure 5a). According to 
SCr, only severe renal insuffi ciency indicates poor outcome, whereas moderate 
renal insuffi ciency does not differ in comparison to normal kidney function. 
(Figure 5b)
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Figure 5a. One-year amputation-free survival for eGFR >60, eGFR 30-60 and eGFR <30 
was 73.2%, 54.7% and 38.7%, respectively.
Figure 5b. One-year AFS for Scr <120, Scr 120–200 and >200 was 69.8%, 46.2% and 
42.2%, respectively.
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2 OUTCOME OF OCTOGENARIANS WITH CLI 
UNDERGOING INFRAINGUINAL REVASCULARIZATION (II)
The life-expectancy of octogenarians with CLI is short (median 2.5 years). 
Five-year survival in the overall series was 36%.
Cox regression analysis showed that advanced age (RR 1.05 95% CI 1.02–
1.08), decreased eGFR (RR 0.99, 95% CI 0.99–1.00), diabetes (RR 1.30, 
95% CI 1.08–1.62), coronary artery disease (RR 1.36, 95%CI 1.05–1.75) and 
bypass surgery (RR 1.55, 95% CI 1.24–1-.93) were associated with decreased 
amputation-free survival.
In the overall series, PTA achieved a signifi cantly better early and late 
outcome than bypass surgery among octogenarians with CLI (Table XI). 
Furthermore, in the 95 propensity-score-matched pairs of patients who 
underwent either PTA or bypass, leg salvage and amputation-free survival 
were signifi cantly better in those who underwent PTA (Table XII).
Classifi cation and regression tree analysis further suggested that PTA was 
associated with better 1-year AFS than bypass surgery, especially in patients 
with CAD (63.8% vs. 48.9% p=0.008).
Table XI. Kaplan-Meier’s estimates of early and late outcome in octogenarians (overall 
series)
30-day 1-year 2-year 3-year 4-year 5-year p-value
SURVIVAL 0.014
PTA 94.9% 66.7% 57.7% 50.4% 42.3% 39.9%
Bypass 90.5% 64.8% 52.3% 40.4% 36.0% 31.5%
LS 0.039
PTA 97.4% 88.8% 85.4% 82.6% 80.2% 78.3%
Bypass 95.0% 79.3% 78.7% 75.4% 73.3% 73.7%
AFS 0.005
PTA 93.1% 62.4% 53.0% 44.3% 35.3% 32.9%
Bypass 86.9% 55.2% 44.9% 33.2% 29.2% 26.1%
PTA = percutaneous transluminal angioplasty, LS= leg salvage, AFS= amputation-free survival
Table XII. Kaplan-Meier’s estimates of early and late outcome in octogenarians (95 
propensity-matched pairs)
30-day 1-year 2-year 3-year 4-year 5-year p-value
SURVIVAL 0.210
PTA 94.7% 67.5% 57.5% 53.3% 46.4% 42.8%
Bypass 91.5% 62.2% 53.5% 48.7% 40.4% 40.4%
LS 0.010
PTA 98.9% 92.1% 87.8% 87.8% 83.4% 83.4%
Bypass 92.5% 76.9% 74.6% 70.7% 62.4% 62.4%
AFS 0.033
PTA 93.6% 63.0% 53.1% 49.1% 40.2% 40.2%
Bypass 86.2% 52.1% 45.1% 37.3% 27.6% 26.1%
PTA= percutaneous transluminal angioplasty, LS= leg salvage, AFS= amputation-free survival
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3 ACCURACY OF THE FINNVASC SCORE AND MODIFIED 
PREVENT III SCORE AS PREDICTORS OF OUTCOME (III)
In the overall series, the accuracy of the Finnvasc and mPIII scoring methods 
in predicting early (30-day) and late (1-year) amputation-free survival (AFS) 
was rather good. The Finnvasc score also seems to be accurate in predicting 
30-day amputation (Table XIII). Both risk scoring methods also predicted 
1-year AFS when isolated endovascular and isolated surgical procedures were 
analysed separately (Table XIV).
Kaplan-Meier estimates for amputation-free survival also show that the 
higher the risk score, the worse the outcome (Figures 6a and b).
Cox regression analysis showed that when adjusted for anatomic level and 
type of revascularization, the Finnvasc score and mPIII score were independent 
predictors of leg salvage, survival and amputation-free survival (Table XV).
Table XIII. Areas under the ROC curve with corresponding 95% CIs for diff erent outcome 
endpoints for the Finnvasc and mPIII score. All procedures are included.
FINNVASC SCORE mPIII SCORE
30-day amputation 0.609 (95%CI 0.549–0.677; p =0.003) 0.533 (95%CI 0.457–0.609; p =0.37)
30- day AFS 0.622 (95% CI 0.573–0.671; p < 0.0001) 0.588 (95%CI 0.533–0.642; p =0 .001)
1 -year AFS 0.630 (95% CI 0.597–0.663; p <0 .0001) 0.634 (95% CI 0.600–0.667; p 0<.0001)
AFS=amputation-free survival
Table XIV. Areas under the ROC curve with corresponding 95% CIs for 1-year AFS 
for the Finnvasc and mPIII score. Endovascular and surgical procedures are analysed 
separately.
FINNVASC SCORE mPIII SCORE
1-year AFS: PTA 0.627 (95% CI 0.584–0.671; p <0.0001) 0.595 (95% CI 0.550–0.640; p <0.0001)
1-year AFS: bypass 0.658 (95% CI 0.612–0.704; p <0.0001) 0.677 (95% CI 0.629–0.725; p <0.0001)
AFS=amputation-free survival, PTA= percutaneous transluminal angioplasty
Table XV. Adjusted Risk ratios (RRs) with corresponding 95% confi dence intervals (CIs) 
of the Finnvasc and mPIII score for diff erent outcome endpoints.
FINNVASC SCORE mPIII SCORE
LS RR 1.322 (95% CI 1.122–1.558; p= 0.001) RR 1.160 (95% CI 1.080–1.247, p < 0.0001)
SURVIVAL RR 1.483 (95% CI 1.344–1.636; p <0.0001) RR 1.241 (95% CI 1.189–1.295; p <0.0001)
AFS RR 1.422 (95% CI 1.319–1.534; p <0.0001) RR 1.219 (95% CI 1.170–1.270; p < 0.0001)
LS=leg salvage, AFS= amputation-free survival
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Figure 6a. Kaplan-Meier estimates for amputation-free survival according to diff erent 
Finnvasc risk scores.
Figure 6b. Kaplan-Meier estimates for amputation-free survival according to diff erent 
modifi ed PIII risk score categories.
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4 RESULTS OF ALTERNATIVE AUTOLOGOUS VEIN 
GRAFT BYPASSES (IV)
Primary patency, assisted primary patency and secondary patency at 1 and 3 
years were signifi cantly better in the single-segment GSV graft group than 
the alternative autologous vein graft group: 74.4% and 67.1% vs. 53.7% and 
42.0% (p<0.0001), 82.4% and 78.1% vs. 67.2% and 57.8% (p<0.0001), and 
84.8% and 80.7% vs. 69.9% and 61.4% (p<0.0001), respectively. Similarly, 
leg salvage at 1 and 3 years was better in the single-segment GSV group: 
88.9% and 87.0% vs. 83.0% and 77.2% (p<0.0001), respectively. The patency, 
survival and leg salvage rates of the different graft types is presented in Table 
XVI.
Table XVI. Kaplan–Meier estimates of patency rates and leg salvage with corresponding 
Standard errors (SEs) for diff erent vein graft types. Numbers in parentheses indicate the 
number of patients at risk.
PP APP SP LS
GSV
1-year
3-year
74.4 ± 1.6 (471)
67.1 ± 1.8 (279)
82.4± 1.4 (508)
78.1 ± 1.6 (279)
84.8 ±1.3 (521)
80.7 ± 1.6 (287)
88.9 ± 1.1 (600)
87.0 ± 1.3 (397)
LSV
1-year
3-year
53.3 ± 17.3 (4)
53.3 ± 17.3 (2)
p>0.001
77.8 ± 13.9 (6)
77.8 ± 13.9 (2)
p>0.001
77.8 ± 13.9 (6)
77.8 ± 13.9 (2)
p>0.001
88.9 ± 10.5 (7)
76.2 ± 14.8 (4)
p=0.008
arm vein
1-year
3-year
62.1 ± 7.7 (24)
43.2 ± 8.2 (12)
p>0.001
74.7 ± 6.9 (29)
55.4 ± 8.6 (15)
p>0.001
74.7 ± 6.9 (29)
58.5 ± 8.4 (16)
p>0.001
85.3 ± 5.5 (33)
76.7 ± 6.9 (17)
p=0.008
spliced vein
1-year
3-year
51.8 ± 3.2 (82)
40.9 ± 3.8 (44)
p>0.001
64.8 ± 3.4 (108)
56.9 ± 3.7 (54)
p>0.001
68.1 ±3.3 (109)
60.7 ±3.7 (69)
p>0.001
82.6 ± 2.6 (150)
77.8 ±3.0 (104)
p=0.008
p-values: compared to the single-segment GSV conduit (Mantel–Cox log rank test)
GSV= great saphenous vein, LSV=lesser saphenous vein
PP= primary patency, APP= assisted primary patency, SP= secondary patency, LS=leg 
salvage
The revision rate of non-single-segment GSV conduits was higher than that 
of single-segment GSV grafts (18% vs. 12%, p= 0.007; Table XVII). In 
multivariate analysis, non-single-segment GSV graft was the only independent 
risk factor for graft stenosis development (RR 2.62, 95% CI 1.56–4.38, 
p<0.0001), graft occlusion (RR 2.27, 95% CI 1.52–3.40, p<0.0001) and graft 
failure (stenosis or occlusion; RR 2.00, 95% CI 1.39–2.88, p<0.0001).
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Table XVII. Rates and types of revision procedures in diff erent graft types.
REVISION TYPE GSV 
(n=818)
LSV 
(n=10)
Arm vein 
(n=42)
Spliced vein 
(n=239)
Total 
(n=1109)
Endovascular
PTA for graft stenosis
infl ow PTA
outfl ow PTA
65
6
2
0
0
0
4
0
0
23
2
0
92
8
2
Surgical
distal extension
patch angioplasty
interposition
8
9
8
2
0
0
2
1
0
9
9
0
21
19
8
Total 98 (12%) 2 (20%) 7 (17%) 43 (18%) 150 (14%)
PTA= percutaneous transluminal angioplasty, GSV= great saphenous vein, LSV= lesser 
saphenous vein
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5 PREDICTORS OF DISMAL OUTCOME AFTER 
INFRAINGUINAL BYPASS FOR CLI (I–IV)
1. One-year survival and amputation-free survival in patients with eGFR<30 
were only 45.7% and 38.7%, respectively (I).
2. Octogenarians undergoing infrainguinal bypass for CLI have poor long-
term survival (at 5 years 31.5%) (II).
3. Of octogenarians with CAD and diabetes undergoing infrainguinal bypass 
for CLI, only 42% are alive with the leg intact at 1 year (II).
4. Patients with a Finnvasc score of 4 or an mPIII score of 8–10 achieved an 
only <40% 1-year AFS (III).
5. High-risk patients (age >80, coronary artery disease, eGFR<30) who 
underwent bypass with an arm vein or spliced vein conduit had extremely 
poor 1-year survival compared to average-risk patients: 28.6% vs. 76.6% 
(p=0.024), respectively (Figure 7) (IV).
Figure 7. Survival estimates for high-risk vs. average-risk patients when an arm or 
spliced vein is used.
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6 ARM VEIN CONDUITS VERSUS PROSTHETIC GRAFTS 
IN INFRAINGUINAL REVACULARIZATIONS FOR CLI (V)
When the patency calculations for the whole study population were performed, 
primary patency at 3 years did not differ statistically signifi cantly between 
arm vein grafts and prosthetic grafts. However, assisted primary patency and 
secondary patency at 3 years were clearly better in the arm vein group (Table 
XIV). In the overall series, the use of a prosthetic graft was a signifi cant risk 
factor for graft occlusion (OR 1.76, 95% CI 1.05–2.90; p =0.031).
In a subgroup analysis of infrapopliteal bypasses, primary patency, assisted 
primary patency and secondary patency rates at 3 years were signifi cantly 
better in the arm vein group (Table XVIII and Figure 7.a-c). The use of a 
prosthetic graft for infrapopliteal revascularization was a signifi cant risk 
factor for graft occlusion (OR 2.95, 95% CI 1.41–6.20; p =0.004). At three 
years, leg salvage was signifi cantly better in the arm vein than the prosthetic 
bypass group (Table XIV).
Splicing did not affect patency. One year primary, assisted primary, and 
secondary patency rates for single-piece, two-piece and three- or four-piece 
arm vein grafts were 61.3%, 49.9%, and 46.3% (p= 0.108), 74.4%, 76.7% and 
67.1% (p= 0.759) and 74.7%, 78.2%, and 67.1% (p= 0.734), respectively.
Table XVIII. Outcome of arm vein versus prosthetic bypasses.
ALL (n=290) FEMOROPOPLITEAL (n=145) INFRAPOPLITEAL (n=145)
Arm vein 
(n=130)
Prosthesis 
(n=160)
Arm vein 
(n=27)
Prosthesis
(n=118)
Arm vein 
(n=103)
Prosthesis 
(n=42)
PP
1-year 55.5% 59.2% 70.3%* 68.8% 51.5% 32.0%
3-year 31.4% 30.3% 43.4%* 36.6% 28.3% 9.6%
p=0.762 p=0.524 p=0.031
APP
1-year 75.4% 63.7% 84.0% 74.1% 73.2% 37.9%
3-year 58.1% 34.8%  63.0%* 42.3% 56.8% 10.4%
p=0.002 p=0.128 p=0.000
SP
1-year 76.0% 66.5% 84.0% 76.8% 73.9% 37.5%
3-year 58.6% 38.1%  63.0%* 46.0% 57.4% 11.2%
p=0.005 p=0.200 p=0.000
LS
1-year 85.4% 86.8% 95.7% 95.3% 82.7% 60.9%
3-year 77.2% 79.7% 84.7% 87.2% 75.0% 57.1%
p=0.631 p=0.953 p=0.005
* standard error > 10%
PP= primary patency, APP= assisted primary patency, SP= secondary patency, LS=leg 
salvage
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Figure 7a-c. In infrapopliteal bypasses a) primary patency (p=0.031), b) assisted primary 
patency (p=0.000) and c) secondary patency (p=0.000) rates were signifi cantly better in 
the arm vein than the prosthetic bypass group.
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7 FEASIBILITY OF EXTERNAL POLYESTER 
SCAFFOLDING FOR COMPROMISED-QUALITY VEIN 
GRAFTS (VI)
The primary, assisted primary and secondary patencies with standard errors 
(SEs) at 6 months were 82.3% (SE ± 6.2%), 88.6% (SE ±4.8%) and 92.1% 
(SE ±4.4%), respectively (Figure 8). In a subgroup of patients with critical 
limb ischaemia, survival and limb salvage at 1 year were 88.2% (SE±6.4%) 
and 90.0% (SE ±6.7%), respectively. 
Figure 8. Primary, assisted primary and secondary patency rates of polyester-scaff olded 
bypasses
A total of six graft stenoses were detected under duplex surveillance. The only 
immediate failure occurred on the third postoperative day and was treated by 
thrombectomy and patch angioplasty of distal anastomosis. There were four 
graft occlusions at 2, 4, 5 and 9 months postoperatively, only one of them 
leading to limb loss. This patient was operated on for critical limb ischaemia. 
In addition to this, another major amputation was performed due to persistent 
gangrene despite patent bypass 6 months after revascularization. There were 
no severe infections related to the polyester mesh tube.
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1 LIMITATIONS OF THE STUDY
Study I: The Modifi cation of Diet in Renal Disease formula has been developed 
and validated for populations with chronic kidney disease. It may not be as 
accurate in patients with no known kidney disease. The estimated GFR seems 
to underestimate actual renal function in patients with normal kidneys. It may 
also overestimate renal function in underweight patients. 
Study II: Despite the propensity score assessment, there were several 
potential confounding factors. Data on preoperative ABI or toe pressures were 
not available for all patients, so it is unclear whether the severity of ischaemia 
was similar in both groups. Differences in the length of the treated arterial 
segments may have occurred, as lesion length was not assessable. Data on 
functional status was lacking due to the retrospective study setting.
Study III: We did not have the data on dialysis status, a risk factor included 
in the modifi ed PIII risk score. Therefore, we assigned 4 points to class V of 
the CKD classifi cation.
Study IV: This is a retrospective study, and the number of patients in the 
subgroups of different vein graft materials, especially in the LSV group, is 
rather small; therefore, there is a possibility of type two statistical errors.
Study V: This is a retrospective analysis, and the number of patients is 
relatively small. One shortcoming of this study is the difference in surveillance 
programmes for vein and prosthetic grafts. Moreover, there might be some 
conduit selection bias, as both arm veins and prostheses were alternatives in 
the femoropopliteal region, but in infrapopliteal bypasses, the arm vein was 
selected whenever not absent. 
Study VI: The limitations of this feasibility study are the lack of a control 
group, a rather short follow-up time and the heterogeneity of the study 
population due to some differences in the indications for polyester mesh use 
between the participating centres.
2 GENERAL DISCUSSION
2.1 Treatment options for CLI and future prospects
As the population ages, increasingly elderly patients with CLI are referred 
to vascular surgeons (Conte et al. 2001, Diehm et al. 2004). The increasing 
number of endovascular revascularizations for CLI (Kudo et al. 2004 ) probably 
directs the patients with the most advanced PAD and a need for the most 
complex revascularizations to vascular surgeons (Norgren et al. 2010). Indeed, 
there is evidence suggesting that the technical complexity of infrainguinal 
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revascularizations has increased compared to the past decades, as is refl ected 
by a greater incidence of gangrene as an indication, an increased need for 
alternative conduits and a more distal outfl ow (Conte et al. 2001). Furthermore, 
the demographics of patients undergoing infrainguinal revascularizations are 
reported to have changed. In addition to higher age and a greater proportion of 
females, the incidence of comorbidities—diabetes, renal failure and previous 
CABG—is reported to have increased (Conte et al. 2001). Vascular surgeons 
are therefore faced with the mounting challenges of treating older, more morbid 
patients with the most advanced forms of CLI. A new challenge for vascular 
surgeons will be the fast increase in the number of ischaemic and neuroischaemic 
ulcerated diabetic feet, in which the healing potential is decreased by infection, 
microvascular dysfunction and other manifestations of neuropathy (Boulton et al. 
2004). The number of these patients will amplify the need for revascularizations, 
especially in the infrapopliteal region, to a large extent. 
In recent years, there has been continuous discussion concerning the best 
revascularization method. Those favouring the endovascular approach refer to 
studies where superior early outcome and lower short-term costs are clearly 
pointed out (Singh 1996, Adam et al. 2005). These advantages are mainly 
due to a lower cardiovascular complication rate and shorter hospital stay 
associated with angioplasty (Nasr 2002, Faglia 2005). In addition to these 
reasons, the rapidly evolving endovascular techniques along with device 
improvement have led to a widespread utilization of the endovascular-fi rst 
approach (Nasr et al. 2002, Salas et al. 2004, Faglia et al. 2005 Brosi et al. 
2007). Admittedly, a limitation of the endovascular approach is the inferior 
durability and subsequent need for repeated interventions (Norgren et al. 
2010). Due to re-operations, however, the survival advantage (Brosi et al. 
2007) and cost-effectiveness (Adam et al. 2005) of angioplasty may diminish 
in the long term.
The great improvements in the endovascular means for revascularization 
underline the importance of the selection of the right patients for the right 
treatment modalities, as bypass surgery is no longer the only available option. 
Despite advanced endovascular techniques, bypass surgery is and probably 
will remain the treatment of choice for complex, multi-level PAD (Norgren et 
al. 2007 and 2010). Moreover, the opponents of infrainguinal bypass usually 
defend their preference by referring to the better durability and subsequent 
improved freedom from re-operations (Adam et al. 2005, Norgren et al. 2007). 
Indeed, this was also confi rmed in our Study II, which suggests that patients 
undergoing bypass had better freedom from further bypasses. However, 
acceptable leg salvage rates can be achieved with both endovascular and surgical 
revascularization. The selection between these treatment modalities should be 
based on patient characteristics (Schanzer et al. 2009, Varu et al. 2010) and not 
on lesion characteristics, as is the case in the TASC classifi cation (Norgren et 
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al. 2007). The most important issue is not which treatment modality is best, 
but which patients gain the most benefi t from angioplasty and who are best 
treated with bypass surgery. 
The older the patients treated, the more important is the selection of the 
right treatment modality. According to Plecha et al. (1985), advanced age is 
associated with increased postoperative mortality after vascular surgery. In 
Study II, bypass and angioplasty in CLI patients aged 80 years or older were 
compared. Angioplasty achieved a better outcome in terms of survival, leg 
salvage and amputation-free survival. A notable fi nding was that the overall life-
expectancy of octogenarians with CLI was short. Hence, the results of Study II 
can be considered similar to those of the Bypass versus Angioplasty in Severe 
Ischaemia of the Leg (BASIL) trial (Adam et al. 2005): patients with a short life 
expectancy achieve better AFS if treated by endovascular intervention. Death 
is a more common endpoint than amputation in very elderly patients, which 
may diminish the infl uence of treatment modality on leg salvage. Furthermore, 
it seems that it is the higher mortality rate after bypass surgery that mostly 
contributes to the signifi cantly better overall outcome of patients treated with 
angioplasty fi rst. In our Study II, perioperative mortality was also much greater 
after bypass surgery than angioplasty. The early survival difference favouring 
endovascular treatment has been reported by others as well (Chang 2001, Salas 
et al. 2004, Brosi et al. 2007, Doslougly et al. 2009). In contrast to these fi ndings, 
a Swedish population-based study (Zdanowski et al. 1998) of patients aged 
76 years and older reported equal perioperative mortality rates of six percent 
for both endovascular and bypass interventions. This probably refl ects the 
severe cardiovascular co-morbidity of these very elderly patients as the major 
determinant of outcome, rather than the treatment modality alone.
New treatment options and improvements in present strategies for CLI is a 
great challenge because a signifi cant proportion of patients may not be eligible 
for revascularization, and medical management at the moment is suboptimal. 
Not only the rapidly evolving endovascular fi eld and device improvements, 
but also the enhanced possibilities of hybrid vascular procedures and the 
continuous improvement in vascular graft technology should be taken into 
consideration in the decision-making. Optimal, best medical treatment will 
probably improve the outcome of both patient and bypass graft. The Prevent 
III (Schanzer et al. 2008) study demonstrated that statin use was associated 
with better one-year survival after revascularization for CLI. There is also 
increasing evidence that statins are benefi cial in the reduction of graft stenoses 
as well (Carter et al. 2007). 
Currently, growth factor gene therapy for angiogenesis (Baumgartner et al. 
1998, Nikol et al. 2008, Powell et al. 2008) and cell therapy using endothelial 
progenitor cells (Tateishi–Yuyama et al. 2002, Huang et al. 2005, Lenk et al. 
2005) in the regeneration of injured endothelium and neoangiogenesis is of 
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great interest. Both gene- and cell-based new therapies in CLI seem promising 
in some patients, but larger randomised trials are needed to prove the effi cacy 
and safety of these therapies. 
2.2 High-risk patient
Renal insuffi ciency, especially end-stage renal disease, is one of the most 
documented independent predictor of poor outcome after bypass surgery for 
CLI (Naidu et al. 2003, Go et al. 2004). Similarly, severe renal insuffi ciency 
was a marker of dismal prognosis in Study I. However, the effect of moderate 
renal insuffi ciency on the outcome of CLI patients is less well documented in 
the literature. Study I demonstrated that not only severe renal insuffi ciency but 
also moderate renal impairment is a predictor of impaired outcome. Although 
renal insuffi ciency is a strong independent predictor of dismal outcome, other 
co-existing morbidities further worsen the outcome, as demonstrated by 
Biancari et al. (2000b, 2002).
Coronary artery disease (Dawson et al. 1993, Farkouh et al. 1994) and 
diabetes (Taylor et al. 1990, Karacagil et al. 1995, Da Silva 1996, Luther and 
Lepäntalo 1997a, Wölfe et al. 2003) are also well-documented risk factors that 
affect the outcome of CLI patients. These factors were not analysed separately 
in the present study. However, Study II demonstrated in octogenarians with 
CLI undergoing infrainguinal bypass that coronary artery disease and diabetes 
further increased the risk of impaired amputation-free survival. End-stage 
renal disease seems to be the only risk factor that per se is a marker of dismal 
prognosis. When outcome is considered, the impact of risk factors seems to be 
more or less cumulative, as was well demonstrated in Study III: the higher the 
score, the poorer the outcome. 
2.3 Outcome assessment
Estimation of the risk of adverse postoperative outcome is of utmost importance 
in patients with CLI, as the outcome of these patients is rather poor with and 
without revascularization procedures (Adam et al. 2005, Lepäntalo and Mätzke 
1996). Hence, several studies during last decades have assessed the outcome 
of lower extremity revascularization procedures and reported a number of risk 
factors associated with poor outcome. The identifi cation of high-risk patients 
by specifi c risk scores might allow more critical decision-making, patient 
selection and a better allocation of resources towards those patients who are 
more likely to benefi t from revascularization. Providing the ideal risk scoring 
method is diffi cult, as the outcome of revascularizations is multi-factorial. In 
addition to the traditional patient- and bypass-related factors discussed in this 
thesis, other aspects such as referral pathway, a multidisciplinary approach 
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(Rith-Najarian et al. 1998) and the activity of the revascularization policy 
(Eskelinen et al. 2003, 2004) have a defi nite impact on outcome. Furthermore, 
functional status seems to be a major contributor to outcome, particularly in 
elderly patients. There is data suggesting that declining functional status in 
patients aged 80 years is associated with poorer survival, leg salvage and 
AFS (Taylor et al. 2005). Goodney et al. (2009) studied the ability to predict 
preoperatively which patient would be ambulatory at 1 year after bypass and 
concluded that advanced age, preoperative non-ambulatory status, dependent 
living status, CLI as indication, graft thrombosis and amputation were 
predictors of amputation and non-ambulatory status. Moreover, dependent 
status combined with age of at least 80 years was associated with an 87-fold 
increase in perioperative death in a recent study by Crawford et al. (2010). 
The inclusion of all possible risk factors into a risk scoring method would 
result in a complicated score not useful in clinical practice. Both risk scoring 
methods evaluated in Study III, the Finnvasc and the mPIII score, are easy 
to use but still rather accurate. This study also demonstrated that although 
these scoring methods were originally derived from a series of CLI patients 
undergoing bypass, they seem to be usable in the risk assessment of patients 
undergoing endovascular revascularization as well. 
The most important benefi t of these scoring methods might be their ability 
to aid in identifying the patients in whom extremely poor outcome estimates 
would suggest that any revascularization is contraindicated and a conservative 
approach being more appropriate. The results of Study III demonstrate that 
a Finnvasc score of 4 and modifi ed PIII score of ≥ 8 are associated with 
remarkably low 1-year amputation-free survival. However, the number of 
these patients with the highest risk was very small (4%–6%). 
2.4 High-risk graft
The superiority of the single-segment great saphenous graft in terms of long-
term patency and leg salvage is indisputable. Unfortunately, optimal graft 
material is not always available. Several studies have introduced characteristics 
of risk grafts: non-single-segment saphenous vein graft (Londrey et al. 1994, 
Alexander et al. 2002, Schazer et al. 2007, Tinder et al. 2008), small-calibre 
vein graft (Idu et al. 1999, Towne 1991 Varty et al. 1993, Wengerter et al. 
1991) and poor-quality vein graft (Pannetta et al. 1992, Wilson et al. 1996) 
are all associated with lower patency rates. Tinder et al. (2004) reported that 
redo bypass was also a risk factor for graft stenosis development. Similarly, 
in the present study (Study IV), a non-single segment great saphenous vein 
was a predictor of graft failure. Although clearly inferior to a single-segment 
GSV, several studies prefer arm veins over prosthetic grafts (Calligaro 
et al. 1997, Faries et al. 2000a, b). Similarly, in Study V, arm veins, even 
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when spliced, were superior to prosthetic grafts especially in infrapopliteal 
bypasses. Furthermore, Study IV suggests that arm veins are prone to stenosis 
development and require duplex surveillance and revision procedures to 
maintain patency. A similar fi nding was published by Armstrong et al. (2004). 
Arm veins are thin-walled and usually have a large diameter especially at 
proximal portions, which might predispose them to ectatic dilatation and 
stenosis development. Indeed, Armstrong et al. (2004) detected both stenoses 
and aneurysmal lesions in arm vein grafts. Most of the stenoses developed 
within one year, but aneurysms developed later, suggesting that arm vein 
bypasses benefi t even from lifelong duplex surveillance. Moreover, arm 
vein bypass is usually the last possible autologous bypass, which should be 
taken into consideration in surveillance activity and risk factor management. 
Study VI suggests that external scaffolding might be useful in arm veins 
and in spliced vein grafts with segments of different sizes, although a larger 
randomised study and longer follow-up will be needed to prove the effect on 
the incidence of vein graft stenosis and graft patency.
2.5 High-risk bypass
The complexity of infrainguinal bypasses largely depends on several factors. 
Compromised infl ow or outfl ow, scar tissue due to previous bypass procedures, 
obesity and a lack of optimal graft material, among other things, make 
revascularization procedures more challenging. Simple prosthetic femoro-
popliteal bypass with good run-off is a completely different operation than a 
redo bypass with a spliced vein graft. Bypasses using alternative autologous 
veins are complex because they are often redo-procedures (Belkin et al. 1995). 
Furthermore, harvesting sometimes several vein segments and suturing vein-
to-vein anastomosis when creating a spliced vein graft is time-consuming. It 
also predisposes the patient to some degree of hypothermia, and perioperative 
bleeding might also be more profuse. Moreover, arm vein harvesting usually 
necessitates general anaestesia. Therefore, secondary bypasses and the use of 
alternative autologous vein grafts can be considered high-risk bypasses. The 
duration and complication risk of these operations might be reduced by having 
at least two surgeons (one harvesting the vein, one preparing anastomosis 
sites), using preoperative vein marking and harvesting arm veins in local 
tumescent anaestesia. 
2.6 Decision-making
The outcome expectations for CLI treatment are not similar for all patients. 
For relatively fi t patients, ulcer healing, pain relief and subsequently sustained 
or improved ambulatory status may be the main goal, whereas for high-risk 
Arvela_vk3.indd   63 14.10.2011   09:06:04
64
patients limb preservation and prolonged survival may be a reasonable result.
The outcome of bypass is largely multifactorial, with varying predominating 
factors, depending on the specifi c outcome of interest. Graft patency and 
subsequent limb salvage are largely determined by the characteristics of the 
graft (graft type and size) and arterial anatomy (run-off). In contrast, patient 
survival is more affected by comorbidiites and medication (Schanzer 2009). 
With modern infrainguinal bypass techniques, patency and leg salvage rates 
are good and durable even in suboptimal circumstances. Patient co-morbidities 
largely determine the overall outcome and should therefore be prioritised in 
the decision-making because a patent bypass is meaningless unless both life 
and limb are preserved. Considering the high-risk nature of CLI per se as well 
as the increasing variety of treatment options, outcome estimation with risk 
assessment is of paramount importance. For low-risk patients with multilevel 
PAD not amenable to endovascular revascularization, it is reasonable to perform 
infrainguinal bypass even in complex circumstances (i.e., redo-operation 
with arm or spliced vein graft). In contrast, for high-risk patients, such high-
risk bypasses should be avoided and other options such as an endovascular 
approach, even in the presence of technical challenges, should be attempted. If 
endovascular revascularization is not feasible, a prosthetic bypass under local 
or regional anaesthesia might be considered. In elderly high-risk patients, 
compromises in patency and revascularization durability may be justifi ed, 
as the life expectancy is short. For non-ambulatory, dependent, high-risk 
patients with limb-threatening ischaemia, primary amputation for decreasing 
mortality might be the most appropriate option. The fi ndings of Studies I–VI, 
with respect to data from the literature, suggest that either the patient’s overall 
condition, the quality of the graft or outfl ow should be good. If all these factors 
are suboptimal, the outcome expectations are extremely poor. Moreover, high-
risk patients (presence of CAD, low eGFR and age >80 years) who underwent 
bypass with an arm or spliced vein graft had extremely poor perioperative and 
1-year survival, suggesting that patients with the highest operative risk should 
not be exposed to high-risk procedures.
In the future, the need of vascular surgery will increase signifi cantly as the 
elderly and diabetic population increases, which emphasises the importance 
of focusing on those patients that will gain benefi t from infrainguinal bypass. 
Therefore, in conclusion, the individual risk of the patient, ambulatory status, 
outcome expectations, the risk of bypass procedure as well as technical factors 
such as the suitability of outfl ow anatomy and the available vein material 
should all be assessed and taken into consideration when deciding on the best 
revascularization strategy.
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CONCLUSIONS
In summary, the fi ndings of Studies I–IV suggest that either the patient’s overall 
condition or the quality of the graft should be acceptable. If both patient and 
graft are considered risky, the outcome expectations are extremely poor. The 
specifi c conclusions were:
1. Renal insuffi ciency—not only renal failure but also moderate impairment 
in renal function—seems to be a signifi cant risk factor for both limb loss 
and death after infrainguinal bypass in patients with critical limb ischaemia. 
Low estimated GFR (<30 ml/min/1.73 m2) is a strong independent marker of 
poor prognosis. Estimated GFR is a more accurate predictor of survival and 
leg salvage after infrainguinal bypass in CLI patients than serum creatinine 
alone. Therefore, GFR estimation should be used instead of creatinine 
level alone in the risk evaluation of patients undergoing infrainguinal 
revascularization for critical limb ischaemia (I).
2. The overall outcome of octogenarians with critical limb ischaemia 
undergoing infrainguinal revascularization is poor. Endovascular treatment 
seems to be associated with a better outcome than bypass in terms of 
survival, leg salvage and amputation-free survival in this fragile patient 
group and should therefore be considered as the fi rst option, especially in 
the presence of coronary artery disease (II).
3. The Finnvasc and modifi ed Prevent III risk scoring methods both predict the 
long-term outcome of patients undergoing both surgical and endovascular 
infrainguinal revascularization for CLI. The Finnvasc score seems to be more 
accurate in predicting immediate postoperative outcome. Both risk scoring 
methods are rather easy to use and might be helpful in clinical practice as an 
aid in preoperative patient selection and decision-making (III).
4. Low estimated eGFR alone, and especially in combination with advanced 
age and CAD, is a marker of dismal survival and AFS. A Finnvasc score of 
4 and mPIII score of >8 are predictors of particularly poor AFS (I–V). 
5. A single-segment great saphenous vein graft is superior to any other 
autologous vein graft in terms of mid-term patency and leg salvage. It requires 
signifi cantly fewer maintenance procedures than alternative autologous vein 
grafts. A non-single segment GSV graft is an independent predictor of both 
graft stenosis development and graft failure. However, due to active duplex 
surveillance and graft maintenance procedures, acceptable patency and leg 
salvage rates can also be achieved with alternative autologous vein grafts 
(IV).
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6. Patients with the combination of high operative risk due to severe 
comorbidities and risk graft have extremely poor survival, suggesting that 
only relatively fi t patients should undergo complex bypasses with risk grafts 
(IV).
7. Arm vein conduits, even when spliced, are superior to prosthetic grafts for 
infrapopliteal bypasses in patients with CLI. Arm veins are often the last-
resource autologous veins for bypass, and they are prone to focal stenoses, 
indicating that the surveillance and maintenance of these “high-risk grafts” 
is important (V). The patency rates of prosthetic bypasses on infrapopliteal 
arteries are only moderate, but the acceptable limb salvage rates justify 
prosthetic infrapopliteal bypasses as a last means of limb salvage. This 
applies especially to high-risk patients with a short life expectancy who do 
not tolerate long, complex procedures with arm or spliced vein grafts (IV, 
V).
8. In the prospective, multicentre study on 50 patients, polyester mesh seemed 
to be a safe and feasible adjunct to infrainguinal bypass using suboptimal 
autologous vein grafts. However, larger prospective, randomised series 
and longer follow-up will be required to prove its safety and benefi t with 
respect to the incidence of vein graft stenosis and graft patency. External 
scaffolding may, however, enable the use of vein grafts of compromised 
quality otherwise unsuitable for bypass grafting (VI).
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